Andrew John Armstrong | Scholars@Duke

Andrew John Armstrong
Associate Professor of Medicine

1. Predictors of sensitivity and clinical efficacy of therapies in advanced prostate cancer
2. Novel designs of clinical trials and pharmacodynamic/translational studies in prostate, kidney, bladder cancer
3. Pre-operative models for drug development of novel agents in human testing in prostate cancer
4. Novel therapies and drug development for prostate, renal, bladder, and testicular cancer
5. Design of rational combination therapies in men with metastatic hormone-refractory prostate cancer
6. PI3 kinase/mTOR inhibition in prostate cancer: mechanisms of sensitivity and resistance
7. Developing prognostic models for progression and survival in metastatic prostate cancer
8. Examining surrogate markers of mortality in metastatic prostate cancer
9. Clear cell and non-clear cell renal cell carcinoma: natural history, sensitivity to novel agents including mTOR and VEGF inhibition

Office Hours

Tuesdays, Wednesdays and Fridays. Contact Peggy Cook, my assistant at peggy.cook@dm.duke.edu for appointments. Or 919-668-4667.

Current Appointments & Affiliations

Associate Professor of Medicine, Medicine, Medical Oncology, Medicine 2014
Associate Professor in Pharmacology and Cancer Biology, Pharmacology & Cancer Biology, Basic Science Departments 2015
Associate Professor in Surgery, Surgery, Urology, Surgery 2017
Member of the Duke Cancer Institute, Duke Cancer Institute, Institutes and Centers 2006

Contact Information

Duke Box 103861, Durham, NC 27710
GSRB1 Room 3006, 905 La Salle St, Durham, NC 27710
andrew.armstrong@duke.edu (919) 668-8797

Background
Education, Training, & Certifications
- M.Sc., Johns Hopkins University 2008
- Fellowship, Division Of Oncology/Hematology, Johns Hopkins University School of Medicine 2003 - 2006
- Internship/Residency, General Internal Medicine, University of Pennsylvania School of Medicine 2000 - 2003
- M.D., University of Virginia School of Medicine 2000
- B.S.E., Duke University 1996
Duke Appointment History
- Associate Professor in Surgery, Surgery, Vascular Surgery, Surgery 2012 - 2017
- Associate Professor of Medicine, Medicine, Medical Oncology, Medicine 2012 - 2014
- Assistant Professor of Medicine, Medicine, Medical Oncology, Medicine 2006 - 2011
- Assistant Professor in Surgery, Surgery, Urology, Surgery 2007 - 2011
Recognition
In the News
- JUN 5, 2018 Duke Health News
  
  Tests Identify Who Would Benefit from Advanced Prostate Cancer Therapies
- MAY 26, 2018 Duke Health News
  
  Bone Scan Software Accurately Calculates Prognosis for Advanced Prostate Cancer
- NOV 9, 2015 WRAL
  
  Moustaches fundraise for cancer in 'Movember' movement
- MAY 18, 2015
  
  Duke-led study clarifies best treatments for uncommon kidney cancers
- NOV 19, 2013
  
  Oral Drug May Improve Survival in Men with Metastatic Prostate Cancer
Expertise
Global Scholarship
- Research
- Teaching
  - China (Country)
Research
Selected Grants
- MK7123 awarded by Merck Sharp & Dohme 2018 - 2023
- NEPC Trial PD-1 Inhibition in Neuroendocrine-like Prostate Cancer (PD-1 Inhibition or Combination Checkpoint Immuntherapy of Neuroedocrine_Like Prostate Cancer awarded by Pfizer, Inc. 2017 - 2022
- A Phase 1B, Open-Label Study of the Safety and Tolerability of Atezolizumab in Combination with Radium-223 Dichloride in Patients with Castrate-Resistant Prostate Cancer who have progressed followinIn awarded by Genentech, Inc. 2017 - 2022
- PCRP Clinical Consortium: Duke University Clinical Research Site awarded by Department of Defense 2007 - 2021
- Plasma Angiome and Serum Androgens as Predictors of Overall Survival in Metastatic Prostate Cancer awarded by Department of Defense 2018 - 2021
- GS-5829 mono and combo enzalutamide awarded by Gilead Sciences, Inc. 2016 - 2021
- A Randomized Phase 2 Study of Sipuleucel-T with or without Radium-223 awarded by Johns Hopkins University 2017 - 2021
- A Phase III, Open Label, Randomized Study to Assess the Efficacy and Safety of Olaparib (Lynparza¿) Versus Enzalutamide or Abiraterone Acetate in Men with Metastatic Castration-Resistant Prostate Canc awarded by AstraZeneca Pharmaceuticals, LP 2018 - 2020
- Pharmacology Industry Internships for Ph.D. Students awarded by American Society for Pharmacology and Experimental Therapeutics 2017 - 2019
- A Phase 2 Trial of the Aurora Kinase A Inhibitor MLN8237 in Patients with Metastatic Castrate Resistant and Neuro awarded by Weill Medical College of Cornell University 2013 - 2019
- STREAM - Salvage Therapeutic Radiation with Enzalutamide and ADT in Men with Recurrent Prostate Cancer awarded by Astellas Pharma Global Development, Inc 2014 - 2019
- CTC-Immune Checkpoints awarded by Janssen Research & Development, LLC 2016 - 2019
- Testing the efficacy of AR degrading compounds in enzalutamide-resistant prostate cancer awarded by Arvinas Inc. 2017 - 2019
- Pharmacodynamic Study of Radium-223 in Men with Bone Metastatic Castration-Resistant Prostate Cancer (CRPC) awarded by Bayer Corporation 2014 - 2018
- Development of Circulating Molecular Predictors of Chemotherapy and Novel Hormonal Therapy Benefit in Men with Metastatic Castration Resistant Prostate Cancer (mCRPC) awarded by Prostate Cancer Foundation 2014 - 2018
- AR variant regulation during EMT and disease progression awarded by National Institutes of Health 2015 - 2018
- A Randomized, Open label, Muiticenter, Phase III, 2 Arm Study of Androgen Deprivation with Leuprilode +/- Docetaxel for awarded by Memorial Sloan Kettering Cancer Center 2013 - 2017
- Prognostic Models of Clinical Outcomes In Men With Castration Resistant Prostate Cancer awarded by National Institutes of Health 2011 - 2016
- Alternative splicing and epithelial-mesenchymal plasticity in prostate tumors awarded by National Institutes of Health 2008 - 2014
Publications & Artistic Works
Selected Publications
- Book Sections
  - Li, J, and Armstrong, AJ. "Prognostic and predictive biomarkers for castration resistant prostate cancer." In Biomarkers in Disease: Methods, Discoveries and Applications: Biomarkers in Cancer, 447-480. January 1, 2015. Full Text
- Conference Papers
  - Armstrong, AJ, Lin, P, Higano, CS, Iversen, P, Sternberg, CN, Tombal, B, Phung, D, Parli, T, Krivoshik, A, and Beer, TM. "Prognostic associations of prostate-specific antigen (PSA) decline with survival, radiographic response and progression in chemotherapy-naiive men with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide." September 2017. Link to Item
  - Armstrong, AJ, Halabi, S, Healy, P, Alumkal, JJ, Winters, C, Kephart, J, Bitting, RL, Hobbs, C, Soleau, CF, Beer, TM, Slottke, R, Mundy, K, Yu, EY, and George, DJ. "Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer." August 2017. Full Text
  - Armstrong, A, Bui, C, Fitch, K, Sawhney, TG, Brown, B, Flanders, S, Balk, M, Deangelis, J, and Chambers, J. "Docetaxel chemotherapy in metastatic castration-resistant prostate cancer: cost of care in Medicare and commercial populations." June 2017. Full Text
  - Armstrong, AJ, Humeniuk, MS, Healy, P, Szmulewitz, R, Winters, C, Kephart, J, Harrison, MR, Martinez, E, Mundy, K, Halabi, S, and George, D. "Phase Ib Trial of Cabazitaxel and Tasquinimod in Men With Heavily Pretreated Metastatic Castration Resistant Prostate Cancer (mCRPC): The CATCH Trial." United States. March 2017. Full Text Link to Item
  - Beer, TM, Armstrong, AJ, Rathkopf, D, Loriot, Y, Sternberg, CN, Higano, CS, Iversen, P, Evans, CP, Kim, C-S, Kimura, G, Miller, K, Saad, F, Bjartell, AS, Borre, M, Mulders, P, Tammela, TL, Parli, T, Sari, S, van Os, S, Theeuwes, A, and Tombal, B. "Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study." February 2017. Full Text
  - Sternberg, C, Armstrong, A, Pili, R, Ng, S, Huddart, R, Agarwal, N, Khvorostenko, D, Lyulko, O, Brize, A, Vogelzang, N, Delva, R, Harza, M, Thanos, A, James, N, Werbrouck, P, Bögemann, M, Hutson, T, Milecki, P, Chowdhury, S, Gallardo, E, Schwartsmann, G, Pouget, J-C, Baton, F, Nederman, T, Tuvesson, H, and Carducci, M. "Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer." August 2016. Full Text
  - Armstrong, AJ, Halabi, S, Healy, P, Lee, WR, Koontz, BF, Moul, JW, Mundy, K, Creel, P, Wood, S, Davis, K, Carducci, MA, Stein, M, Hobbs, C, Reimer, B, Nguyen, M, Anand, M, Bratt, L, Kim, S, Tran, PT, George, DJ, and Department of Defense Prostate Cancer Clinical Trials Consortium, . "A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy in men with PSA recurrent prostate cancer after radical prostatectomy." March 2016. Full Text
  - Armstrong, AJ, Higano, CS, Sartor, AO, Vogelzang, NJ, Berry, WR, Penson, DF, Kassabian, V, Nordquist, LT, Chang, NN, LIll, JS, and Cooperberg, MR. "Changing characteristics of patients treated with sipuleucel-T (sip-T) over time: Real-world experience from the PROCEED registry." January 10, 2016. Full Text
  - Armstrong, AJ, Saad, F, Shore, ND, Fizazi, K, Phung, D, Dmuchowski, CF, Hirmand, M, Forer, D, Scher, HI, and De Bono, JS. "Surrogacy analysis of prostate-specific antigen (PSA) decline for improved overall survival (OS) with enzalutamide (ENZ) in AFFIRM." January 10, 2016. Full Text
  - George, DJ, Halabi, S, Healy, P, Gemberling, S, Winters, C, Mundy, K, Harrison, MR, Szmulewitz, RZ, and Armstrong, AJ. "Phase Ib trial of docetaxel, prednisone, and pazopanib, in men with metastatic castration resistant prostate cancer (mCRPC)." January 10, 2016. Full Text
  - Higano, CS, Armstrong, AJ, Cooperberg, MR, Concepcion, RS, Tutrone, RF, Olsson, CA, Pieczonka, CM, Shore, ND, Chang, NN, LIll, JS, and Sartor, AO. "Analysis of the PROCEED registry by baseline prostate-specific antigen (PSA) quartiles: Preliminary analysis of real-world sipuleucel-T (sip-T) use." January 10, 2016. Full Text
  - Morris, MJ, Beer, TM, Loriot, Y, Higano, CS, Armstrong, AJ, Sternberg, CN, De Bono, JS, Tombal, BF, Parli, T, Bhattacharya, S, Krivoshik, AP, Phung, D, and Rathkopf, DE. "Correlation between radiographic progression-free survival (rPFS) and overall survival (OS): Results from PREVAIL." January 10, 2016. Full Text
  - Penson, DF, Armstrong, AJ, Concepcion, RS, Wu, K, Wang, F, Krivoshik, AP, Phung, D, and Higano, CS. "Sensitivity analyses for progression-free survival (PFS) and radiographic PFS (rPFS) from the phase II STRIVE trial comparing enzalutamide (ENZA) with bicalutamide (BIC) in men with castration-resistant prostate cancer (CRPC)." January 10, 2016. Full Text
  - Sartor, AO, Cooperberg, MR, Armstrong, AJ, Vogelzang, NJ, Vacirca, JL, Scholz, MC, Dakhil, SR, Nordquist, LT, Heath, EI, Chang, NN, LIll, JS, and Higano, CS. "Real-world experience of therapeutic sequencing and time to first anticancer intervention (ACI) following sipuleucel-T (sip-T): Initial data from the PROCEED registry." January 10, 2016. Full Text
  - Sternberg, CN, Armstrong, AJ, Pili, R, Nederman, T, and Carducci, MA. "A Phase 3, randomized, double-blind, placebo-controlled study of tasquinimod (TASQ) in men with metastatic castration-resistant prostate cancer (mCRPC), secondary endpoints." January 10, 2016. Full Text
  - Ware, KE, Schaeffer, D, Zhang, T, Garcia-Blanco, MA, and Armstrong, AJ. "Abstract 1847: AR-V7 regulation during epithelial plasticity." August 1, 2015. Full Text
  - Armstrong, AJ, Broderick, S, Eisen, T, Stadler, WM, Jones, RJ, Garcia, JA, Vaishampayan, UN, Picus, J, Hawkins, RE, Hainsworth, JD, Kollmannsberger, CK, Logan, TF, Puzanov, I, Pickering, LM, Ryan, CW, Protheroe, A, Lusk, CM, Oberg, S, Halabi, S, and George, DJ. "Final clinical results of a randomized phase II international trial of everolimus vs. sunitinib in patients with metastatic non-clear cell renal cell carcinoma (ASPEN)." May 20, 2015. Link to Item
  - Higano, CS, Sartor, AO, Vogelzang, NJ, Dakhil, SR, Concepcion, RS, Pieczonka, CM, Vacirca, JL, Tutrone, RF, Olsson, CA, Penson, DF, Biggs, C, Lill, JS, Gray, TE, McCoy, C, Cooperberg, MR, and Armstrong, AJ. "Administration of sipuleucel-T (sip-T) infusions (infs) outside of the clinical trial setting: Data from the PROCEED registry." May 20, 2015. Link to Item
  - Li, J, Beaver, J, Bitting, RL, Gregory, S, and Armstrong, AJ. "Genomic analysis of circulating tumor cells (CTCs) from men with metastatic castration resistant prostate cancer (mCRPC) in the context of enzalutamide therapy." May 20, 2015. Link to Item
  - Morris, MJ, Hilden, P, Gleave, ME, Armstrong, AJ, Carducci, MA, Saad, F, Dayan, ES, Filipenko, J, Acosta, I, Heller, G, and Scher, HI. "Efficacy analysis of a phase III study of androgen deprivation therapy (ADT) +/- docetaxel (D) for men with biochemical relapse (BCR) after prostatectomy." May 20, 2015. Link to Item
  - Scher, HI, Morris, MJ, Stadler, WM, Higano, CS, Halabi, S, Smith, MR, Basch, EM, Fizazi, K, Ryan, CJ, Antonarakis, ES, Corn, PG, Liu, G, De Bono, JS, Schwartz, LH, Beer, TM, Kelly, WK, Hussain, M, Sartor, AO, Kantoff, PW, and Armstrong, AJ. "The Prostate Cancer Working Group 3 (PCWG3) consensus for trials in castration-resistant prostate cancer (CRPC)." May 20, 2015. Link to Item
  - Zhang, T, Boominathan, R, Foulk, B, Connelly, MC, Rao, C, Kemeny, G, Strickler, JH, Abbruzzese, JL, Harrison, MR, George, DJ, Hurwitz, H, Garcia-Blanco, MA, and Armstrong, AJ. "Evaluation of a novel c-MET based circulating tumor cell (CTC) biomarker in patients with gastrointestinal (GI) and genitourinary (GU) malignancies." May 20, 2015. Link to Item
  - Graff, JN, Baciarello, G, Armstrong, AJ, Higano, CS, Iversen, P, Forer, D, Mansbach, HH, Phung, D, Tombal, BF, Beer, TM, and Sternberg, CN. "Clinical outcomes and safety in men ≥ 75 and < 75 years with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide in the phase 3 PREVAIL trial." March 2015. Full Text
  - Tutrone, RF, Ahaghotu, C, Armstrong, AJ, Higano, CS, Cooperberg, MR, Belkoff, LH, Olsson, CA, Goel, S, Tyler, RC, LIll, JS, Gray, TE, McCoy, C, and Sartor, AO. "Characteristics of African Americans (AAs) treated with sipuleucel-T (sip-T): Comparison of clinical trial and real-world experience." March 2015. Full Text
  - Zhang, T, Boominathan, R, Foulk, B, Connelly, MC, Rao, C, Kemeny, G, Hurwitz, H, Garcia-Blanco, MA, and Armstrong, AJ. "Evaluation of a novel c-MET based circulating tumor cell (CTC) biomarker in patients with gastrointestinal malignancies." January 20, 2015. Full Text
  - Bhavsar, NA, Harrison, MR, Howie, LJ, Armstrong, AJ, Davis, K, Chen, Q, Pupa, MR, Abernethy, A, George, DJ, and Hirsch, BR. "1072PEXPERIENCE OF PATIENTS TREATED WITH SIPULEUCEL-T IN AN ACADEMIC SETTING." September 2014.
  - Furay, A, Nordquist, L, Dakhil, S, Green, N, Heath, E, Tutrone, R, Vogelzang, N, Armstrong, A, Cooperberg, M, Tyler, R, Whitmore, J, and Higano, C. "Impact of Prior Radiation Treatment on Sipuleucel-T Product Parameters in PROCEED Patients." September 2014. Full Text
  - Armstrong, AJ, Tombal, B, Sternberg, CN, Higano, CS, Rathkopf, DE, Loriot, Y, Saad, F, Joshua, AM, De Bono, JS, Venner, PM, Caries, J, Mainwaring, PN, Evans, CP, Noonberg, SB, Mansbach, HH, Bhattacharya, S, Perabo, F, Phung, D, and Beer, TM. "Primary, secondary, and quality-of-life endpoint results from PREVAIL, a phase 3 study of enzalutamide in men with metastatic castration resistant prostate cancer (mCRPC)." May 20, 2014. Link to Item
  - Halabi, S, Kelly, WK, Zhou, H, Armstrong, AJ, Quinn, D, Fizazi, K, Solomon, NC, Tannock, I, Petrylak, DP, Morris, MJ, and Small, EJ. "The site of visceral metastases (mets) to predict overall survival (OS) in castration-resistant prostate cancer (CRPC) patients (pts): A meta-analysis of five phase III trials." May 20, 2014. Link to Item
  - Li, J, Beaver, J, Bitting, RL, Gregory, S, and Armstrong, AJ. "Genomic analysis of circulating tumor cells (CTCs) from men with metastatic castration resistant prostate cancer (mCRPC) in the context of enzalutamide therapy." May 20, 2014. Link to Item
  - Morris, MJ, Gleave, ME, Armstrong, AJ, Carducci, MA, Saad, F, Lacuna, KP, and Scher, HI. "A randomized, open label, multicenter, phase 3, 2-arm study of androgen deprivation with leuprolide (L), +/- docetaxel (D) for clinically asymptomatic prostate cancer (PC) subjects with a rising PSA following definitive local therapy: Safety results." May 20, 2014. Link to Item
  - Morris, MJ, Loriot, Y, Beer, TM, Higano, CS, Armstrong, AJ, Sternberg, CN, De Bono, JS, Tombal, BF, Noonberg, SB, Mansbach, HH, Bhattacharya, S, Perabo, F, Phung, D, and Rathkopf, DE. "Sensitivity analyses for radiographic progression-free survival (rPFS): Results from the phase 3 PREVAIL trial comparing enzalutamide to placebo." May 20, 2014. Link to Item
  - Zhang, T, Dhawan, MS, Healy, P, George, DJ, Olden, J, Chin, B, and Armstrong, AJ. "Clinical benefit of docetaxel or enzalutamide after progression on first-line abiraterone acetate and prednisone in men with metastatic castration resistant prostate cancer (mCRPC)." May 20, 2014. Link to Item
  - Armstrong, AJ, Bitting, RL, Kemeny, G, and George, DJ. "Evidence for circulating tumor cell (CTC) alkaline phosphatase (AP) expression in men with bone-metastatic castration-resistant prostate cancer (CRPC) during abiraterone acetate treatment." February 2014. Full Text
  - Armstrong, AJ, Li, J, Beaver, J, Bitting, RL, and Gregory, S. "Genomic analysis of circulating tumor cells (CTCs) from men with metastatic castration resistant prostate cancer (mCRPC) in the context of enzalutamide therapy." February 2014. Full Text
  - Beer, TM, Armstrong, AJ, Sternberg, CN, Higano, CS, Iversen, P, Loriot, Y, Rathkopf, DE, Bhattacharya, S, Carles, J, De Bono, JS, Evans, CP, Joshua, AM, Kim, C-S, Kimura, G, Mainwaring, PN, Mansbach, HH, Miller, K, Noonberg, SB, Venner, PM, and Tombal, B. "Enzalutamide in men with chemotherapy-naive metastatic prostate cancer (mCRPC): Results of phase III PREVAIL study." February 2014. Full Text
  - Finkelstein, SE, Nordquist, LT, Dakhil, SR, Green, NB, Heath, EI, Tutrone, R, Vogelzang, NJ, Armstrong, AJ, Cooperberg, MR, Tyler, RC, Sims, RB, Whitmore, JB, and Higano, CS. "Impact of prior radiation treatment (tx) on sipuleucel-T (sip-T) product parameters in PROCEED patients (pts)." February 2014. Full Text
  - Nabhan, C, Sartor, AO, Cooperberg, MR, Armstrong, AJ, Vacirca, JL, Concepcion, RS, Berry, WR, Dhawan, M, Tutrone, R, Sandler, A, McCoy, C, Whitmore, JB, Tyler, RC, and Higano, CS. "Sipuleucel-T in metastatic castration-resistant prostate cancer (mCRPC) patients ≥80 years-old: Data from PROCEED." February 2014. Full Text
  - Vogelzang, NJ, Vacirca, JL, Kantoff, PW, Scholz, MC, Dakhil, SR, Nordquist, LT, Higano, CS, Sartor, AO, Cooperberg, MR, Sandler, A, McCoy, C, Whitmore, JB, Tyler, RC, and Armstrong, AJ. "Effect of prior abiraterone (ABI) or enzalutamide (ENZ) on sipuleucel-T (sip-T) manufacture in PROCEED patients (pts)." February 2014. Full Text
  - Armstrong, AJ, Halabi, S, Eisen, T, Stadler, WM, Jones, RR, Vaishampayan, UN, Garcia, JA, Hawkins, RE, Kollmannsberger, CK, Lusk, C, Broderick, S, and George, DJ. "ASPEN: A randomized phase II trial of everolimus versus sunitinib in patients with metastatic non-clear cell renal cell carcinoma." May 20, 2013. Link to Item
  - Armstrong, AJ, Kaboteh, R, Carducci, MA, Damber, J-E, Stadler, WM, Mats, H, Edenbrandt, L, Forsberg, G, Nordle, O, Pili, R, and Morris, MJ. "Association of bone scan index (BSI) with prognostic biomarkers and survival in men with metastatic castration-resistant prostate cancer (mCRPC) enrolled in a prospective randomized controlled trial of tasquinimod." May 20, 2013. Link to Item
  - Bitting, RL, Healy, P, Halabi, S, George, DJ, Ko, JH, and Armstrong, AJ. "Evaluation of clinical phenotype, survival, and circulating tumor cell (CTC) enumeration in men with metastatic castration-resistant prostate cancer (mCRPC)." May 20, 2013. Link to Item
  - Halabi, S, Lin, C-Y, Small, EJ, Armstrong, AJ, Kaplan, EB, Petrylak, DP, Sternberg, CN, Shen, L, Oudard, S, De Bono, JS, and Sartor, AO. "A prognostic model for predicting overall survival in metastatic castrate-resistant prostate cancer (mCRPC) men treated with second-line chemotherapy." May 20, 2013. Link to Item
  - Higano, CS, Armstrong, AJ, Cooperberg, MR, Kantoff, PW, Bailen, J, Concepcion, RS, Kassabian, V, Dakhil, SR, Finkelstein, SE, Vacirca, JL, Rifkin, RM, Sandler, A, McCoy, C, Whitmore, JB, Tyler, C, and Sartor, AO. "Impact of prior docetaxel (D) on sipuleucel-T (sip-T) product parameters in PROCEED patients (pts)." May 20, 2013. Link to Item
  - Armstrong, AJ, Shen, T, Halabi, S, Kemeny, G, Bitting, RL, Kartcheske, P, Embree, E, Morris, K, Winters, C, Jaffe, T, Fleming, MT, and George, DJ. "A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer." February 20, 2013. Full Text
  - Halabi, S, Lin, C-Y, Small, EJ, Armstrong, AJ, Kaplan, EB, Petrylak, DP, Sternberg, CN, Shen, L, Oudard, S, De Bono, JS, and Sartor, AO. "A model for predicting overall survival in men with metastatic castrate-resistant prostate cancer (CRPC) for whom first-line chemotherapy failed." February 20, 2013. Full Text Link to Item
  - Scher, HI, Fizazi, K, Saad, F, Chi, KN, Taplin, M-E, Sternberg, CN, Armstrong, AJ, Hirmand, M, Forer, D, and De Bono, JS. "Impact of on-study corticosteroid use on efficacy and safety in the phase III AFFIRM study of enzalutamide (ENZA), an androgen receptor inhibitor." February 20, 2013. Full Text Link to Item
  - Schweizer, MT, Bardia, A, Blackford, AL, Lin, J, Armstrong, AJ, King, S, Rudek, MA, Yegnasubramanian, ST, and Carducci, MA. "A prostate cancer clinical trials consortium trial of disulfiram (D) in men with nonmetastatic recurrent prostate cancer (PCa)." February 20, 2013. Full Text Link to Item
  - Corman, J, Dawson, N, Hall, S, Nabhan, C, Ferrari, A, Armstrong, AJ, Murdock, MI, Stewart, F, Sheikh, N, and Petrylak, DP. "OPENACT: PHASE 2, OPEN-LABEL STUDY OF SIPULEUCEL-T IN METASTATIC CASTRATE-RESISTANT PROSTATE CANCER (MCRPC)." September 2012. Link to Item
  - Scher, HI, Fizazi, K, Saad, F, Chi, K, Taplin, M, Sternberg, CN, Armstrong, AJ, Hirmand, M, Selby, B, and de Bono, JS. "ASSOCIATION OF BASELINE CORTICOSTEROID WITH OUTCOMES IN A MULTIVARIATE ANALYSIS OF THE PHASE 3 AFFIRM STUDY OF ENZALUTAMIDE (ENZA), AN ANDROGEN RECEPTOR SIGNALING INHIBITOR (ARSI)." September 2012. Link to Item
  - Sonpavde, G, Pond, GR, Armstrong, AJ, Galsky, MD, Wood, BA, Wang, S, Paolini, J, Lechuga, M, Smith, MR, and Michaelson, MD. "ASSOCIATION OF PROGRESSION BY PROSTATE CANCER WORKING GROUP (PCWG)-2 CRITERIA AND SURVIVAL IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER." September 2012. Link to Item
  - Armstrong, AJ, Haggman, M, Stadler, WM, Gingrich, JR, Assikis, VJ, Polikoff, J, Denmeade, SR, George, DJ, Andreou, C, Clark, WR, Sieber, P, Agajanian, R, Belkoff, L, Damber, J-E, Nordle, O, Forsberg, G, Carducci, MA, and Pili, R. "Tasquinimod and survival in men with metastatic castration-resistant prostate cancer: Results of long-term follow-up of a randomized phase II placebo-controlled trial." May 20, 2012. Link to Item
  - Bitting, RL, Boominathan, R, Rao, C, Embree, E, George, DJ, Connelly, MC, Kemeny, G, Garcia-Blanco, M, and Armstrong, AJ. "Isolation of circulating tumor cells using a novel EMT-based capture method." May 20, 2012. Link to Item
  - De Bono, JS, Fizazi, K, Saad, F, Taplin, M-E, Sternberg, CN, Miller, K, Mulders, P, Chi, KN, Armstrong, AJ, Hirmand, M, Selby, B, Scher, HI, and Investigators, AFFIRM. "Primary, secondary, and quality-of-life endpoint results from the phase III AFFIRM study of MDV3100, an androgen receptor signaling inhibitor." May 20, 2012. Link to Item
  - Halabi, S, Armstrong, AJ, Sartor, AO, De Bono, JS, Kaplan, EB, and Small, EJ. "Prostate-specific antigen decline (PSA) as a surrogate for overall survival (OS) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) who failed first-line chemotherapy." May 20, 2012. Link to Item
  - George, DJ, Halabi, S, Zurita, AJ, Creel, P, Mundy, K, Turnbull, JD, Yenser Wood, SE, Armstrong, AJ, Varley, RJ, Madden, J, and Moul, JW. "Investigator-initiated pilot study of sunitinib malate in patients with newly diagnosed prostate cancer prior to prostatectomy: A trial of the DoD/PCF Prostate Cancer Clinical Trials Consortium." May 20, 2011. Full Text
  - Araujo, J, Mathew, P, Armstrong, A, Braud, E, Posadas, E, Lonberg, M, Gallick, G, Trudel, G, Paliwal, P, and Logothetis, C. "7028 Dasatinib and docetaxel combination treatment for patients with metastatic castration-resistant prostate cancer (CRPC): analysis of Study CA180–086." September 2009. Full Text
  - Araujo, J, Armstrong, AJ, Braud, EL, Posadas, E, Lonberg, M, Gallick, GE, Trudel, GC, Paliwal, P, Agrawal, S, and Logothetis, CJ. "Dasatinib and docetaxel combination treatment for patients with castration-resistant progressive prostate cancer: A phase I/II study (CA180086)." May 20, 2009. Link to Item
  - Armstrong, AJ, Halabi, S, Tannock, IF, George, DJ, Dewit, R, and Eisenberger, M. "Development of risk groups in metastatic castration-resistant prostate cancer (mCRPC) to facilitate the identification of active chemotherapy regimens." May 20, 2009. Link to Item
  - Armstrong, AJ. "Commentary." September 1, 2008.
- Journal Articles
  - Humeniuk, MS, Gupta, RT, Healy, P, McNamara, M, Ramalingam, S, Harrison, M, George, D, Zhang, T, Wu, Y, and Armstrong, AJ. "Platinum sensitivity in metastatic prostate cancer: does histology matter?." Prostate cancer and prostatic diseases 21, no. 1 (April 2018): 92-99. Full Text
  - Rathkopf, DE, Beer, TM, Loriot, Y, Higano, CS, Armstrong, AJ, Sternberg, CN, de Bono, JS, Tombal, B, Parli, T, Bhattacharya, S, Phung, D, Krivoshik, A, Scher, HI, and Morris, MJ. "Radiographic Progression-Free Survival as a Clinically Meaningful End Point in Metastatic Castration-Resistant Prostate Cancer: The PREVAIL Randomized Clinical Trial." JAMA oncology (March 8, 2018). Full Text
  - Austin, RG, Huang, TJ, Wu, M, Armstrong, AJ, and Zhang, T. "Clinical utility of non-EpCAM based circulating tumor cell assays." Advanced drug delivery reviews 125 (February 2018): 132-142. (Review) Full Text
  - Zhu, J, Armstrong, AJ, Friedlander, TW, Kim, W, Pal, SK, George, DJ, and Zhang, T. "Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond." Journal for immunotherapy of cancer 6, no. 1 (January 25, 2018): 4-. (Review) Full Text Open Access Copy
  - Armstrong, AJ, Antonarakis, ES, Taplin, M-E, Kelly, WK, Beltran, H, Fizazi, K, Dahut, WL, Shore, N, Slovin, S, George, D, Carducci, MA, Corn, P, Danila, D, Dreicer, R, Heath, E, Rathkopf, D, Liu, G, Nanus, D, Stein, M, Smith, MR, Sternberg, C, Wilding, G, Nelson, PS, Halabi, S, Kantoff, P, Clarke, NW, Evans, CP, Heidenreich, A, Mottet, N, Gleave, M, Morris, MJ, and Scher, HI. "Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet." Annals of oncology : official journal of the European Society for Medical Oncology 29, no. 1 (January 2018): 23-25. Full Text
  - McNamara, M, Sweeney, C, Antonarakis, ES, and Armstrong, AJ. "The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation." Prostate cancer and prostatic diseases (December 20, 2017). (Review) Full Text
  - Taplin, M-E, Armstrong, AJ, Lin, P, Krivoshik, A, Phung, D, Parli, T, Tombal, B, and Beer, TM. "Clinical Outcomes of Chemotherapy Naïve Men with Metastatic Castration Resistant Prostate Cancer and Low Baseline Prostate Specific Antigen Treated with Enzalutamide vs Placebo." The Journal of urology 198, no. 6 (December 2017): 1324-1332. Full Text
  - Zhu, J, Tucker, M, Wang, E, Grossman, JS, Armstrong, AJ, George, DJ, and Zhang, T. "Acute Myeloid Leukemia After Olaparib Treatment in Metastatic Castration-Resistant Prostate Cancer." Clinical genitourinary cancer 15, no. 6 (December 2017): e1137-e1141. Full Text
  - Zhang, T, and Armstrong, AJ. "The Who, What, and How of Cabazitaxel Treatment in Metastatic Castration-Resistant Prostate Cancer." Journal of clinical oncology : official journal of the American Society of Clinical Oncology 35, no. 28 (October 2017): 3175-3177. Full Text
  - Zhang, T, and Armstrong, AJ. "The who, what, and how of cabazitaxel treatment in metastatic castration-resistant prostate cancer." Journal of Clinical Oncology 35, no. 28 (October 1, 2017): 3175-3177. Full Text
  - Humeniuk, MS, Zhang, T, and Armstrong, AJ. "Exploiting DNA damage without repair: The activity of platinum chemotherapy in BRCA-mutated prostate cancers." Cancer 123, no. 18 (September 2017): 3441-3444. Full Text
  - Humeniuk, MS, and Armstrong, AJ. "RECISTing the Temptation to Prematurely Stop Nivolumab." European urology 72, no. 3 (September 2017): 377-378. Full Text
  - Armstrong, AJ, Halabi, S, Healy, P, Alumkal, JJ, Winters, C, Kephart, J, Bitting, RL, Hobbs, C, Soleau, CF, Beer, TM, Slottke, R, Mundy, K, Yu, EY, and George, DJ. "Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer." EUROPEAN JOURNAL OF CANCER 81 (August 2017): 228-236. Full Text Link to Item
  - Armstrong, AJ, Saad, F, Phung, D, Dmuchowski, C, Shore, ND, Fizazi, K, Hirmand, M, Forer, D, Scher, HI, and Bono, JD. "Clinical outcomes and survival surrogacy studies of prostate-specific antigen declines following enzalutamide in men with metastatic castration-resistant prostate cancer previously treated with docetaxel." Cancer 123, no. 12 (June 2017): 2303-2311. Full Text
  - Bryce, AH, Alumkal, JJ, Armstrong, A, Higano, CS, Iversen, P, Sternberg, CN, Rathkopf, D, Loriot, Y, de Bono, J, Tombal, B, Abhyankar, S, Lin, P, Krivoshik, A, Phung, D, and Beer, TM. "Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL." Prostate cancer and prostatic diseases 20, no. 2 (June 2017): 221-227. Full Text
  - Ramalingam, S, Humeniuk, MS, Hu, R, Rasmussen, J, Healy, P, Wu, Y, Harrison, MR, Armstrong, AJ, George, DJ, and Zhang, T. "Prostate-specific antigen response in black and white patients treated with abiraterone acetate for metastatic castrate-resistant prostate cancer." Urol Oncol 35, no. 6 (June 2017): 418-424. Full Text Link to Item
  - Ware, KE, Gilja, S, Xu, S, Shetler, S, Jolly, MK, Wang, X, Bartholf Dewitt, S, Hish, AJ, Jordan, S, Eward, W, Levine, H, Armstrong, AJ, and Somarelli, JA. "Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells." Journal of visualized experiments : JoVE , no. 122 (April 7, 2017). Full Text
  - Sonpavde, G, and Armstrong, AJ. "Drug development in prostate cancer: time to embrace RECIST?." The Lancet. Oncology 18, no. 4 (April 2017): 419-421. Full Text
  - Armstrong, AJ, Humeniuk, MS, Healy, P, Szmulewitz, R, Winters, C, Kephart, J, Harrison, MR, Martinez, E, Mundy, K, Halabi, S, and George, D. "Phase Ib Trial of Cabazitaxel and Tasquinimod in Men With Heavily Pretreated Metastatic Castration Resistant Prostate Cancer (mCRPC): The CATCH Trial." PROSTATE 77, no. 4 (March 1, 2017): 385-395. Full Text Link to Item
  - Armstrong, AJ. "Prognostic and predictive biomarkers in metastatic castration-resistant prostate cancer." Clinical advances in hematology & oncology : H&O 15, no. 3 (March 2017): 184-188.
  - Gupta, S, Li, J, Kemeny, G, Bitting, RL, Beaver, J, Somarelli, JA, Ware, KE, Gregory, S, and Armstrong, AJ. "Whole Genomic Copy Number Alterations in Circulating Tumor Cells from Men with Abiraterone or Enzalutamide-Resistant Metastatic Castration-Resistant Prostate Cancer." Clinical cancer research : an official journal of the American Association for Cancer Research 23, no. 5 (March 2017): 1346-1357. Full Text
  - Beer, TM, Armstrong, AJ, Rathkopf, D, Loriot, Y, Sternberg, CN, Higano, CS, Iversen, P, Evans, CP, Kim, C-S, Kimura, G, Miller, K, Saad, F, Bjartell, AS, Borre, M, Mulders, P, Tammela, TL, Parli, T, Sari, S, van Os, S, Theeuwes, A, and Tombal, B. "Enzalutamide in Men with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study." EUROPEAN UROLOGY 71, no. 2 (February 2017): 151-154. Full Text Link to Item
  - Penson, DF, Armstrong, AJ, Concepcion, R, Agarwal, N, Olsson, C, Karsh, L, Dunshee, C, Wang, F, Wu, K, Krivoshik, A, Phung, D, and Higano, CS. "Reply to M.A.N. Şendur et al and J. Michels." Journal of clinical oncology : official journal of the American Society of Clinical Oncology 35, no. 1 (January 2017): 123-. Full Text
  - Ramalingam, S, Eisenberg, A, Foo, WC, Freedman, J, Armstrong, AJ, Moss, LG, and Harrison, MR. "Treatment-related neuroendocrine prostate cancer resulting in Cushing's syndrome." Int J Urol 23, no. 12 (December 2016): 1038-1041. Full Text Link to Item
  - Armstrong, AJ. "Predictive medicine: Using circulating biomarkers to guide management of patients with genitourinary cancers." Urologic oncology 34, no. 11 (November 2016): 488-489. Full Text
  - Evans, CP, Higano, CS, Keane, T, Andriole, G, Saad, F, Iversen, P, Miller, K, Kim, C-S, Kimura, G, Armstrong, AJ, Sternberg, CN, Loriot, Y, de Bono, J, Noonberg, SB, Mansbach, H, Bhattacharya, S, Perabo, F, Beer, TM, and Tombal, B. "The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer." European urology 70, no. 4 (October 2016): 675-683. Full Text
  - Somarelli, JA, Shetler, S, Jolly, MK, Wang, X, Bartholf Dewitt, S, Hish, AJ, Gilja, S, Eward, WC, Ware, KE, Levine, H, Armstrong, AJ, and Garcia-Blanco, MA. "Mesenchymal-Epithelial Transition in Sarcomas Is Controlled by the Combinatorial Expression of MicroRNA 200s and GRHL2." Molecular and cellular biology 36, no. 19 (October 2016): 2503-2513. Full Text Open Access Copy
  - Antonarakis, ES, Armstrong, AJ, Dehm, SM, and Luo, J. "Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting." Prostate cancer and prostatic diseases 19, no. 3 (September 2016): 231-241. (Review) Full Text
  - Shields Iv, CW, Wang, JL, Ohiri, KA, Essoyan, ED, Yellen, BB, Armstrong, AJ, and López, GP. "Magnetic separation of acoustically focused cancer cells from blood for magnetographic templating and analysis." Lab on a chip 16, no. 19 (September 2016): 3833-3844. Full Text
  - Somarelli, JA, Schaeffer, D, Marengo, MS, Bepler, T, Rouse, D, Ware, KE, Hish, AJ, Zhao, Y, Buckley, AF, Epstein, JI, Armstrong, AJ, Virshup, DM, and Garcia-Blanco, MA. "Distinct routes to metastasis: plasticity-dependent and plasticity-independent pathways." Oncogene 35, no. 33 (August 2016): 4302-4311. Full Text Open Access Copy
  - Ware, KE, Somarelli, JA, Schaeffer, D, Li, J, Zhang, T, Park, S, Patierno, SR, Freedman, J, Foo, W-C, Garcia-Blanco, MA, and Armstrong, AJ. "Snail promotes resistance to enzalutamide through regulation of androgen receptor activity in prostate cancer." Oncotarget 7, no. 31 (August 2016): 50507-50521. Full Text Open Access Copy
  - Penson, DF, Armstrong, AJ, Concepcion, R, Agarwal, N, Olsson, C, Karsh, L, Dunshee, C, Wang, F, Wu, K, Krivoshik, A, Phung, D, and Higano, CS. "Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial." Journal of clinical oncology : official journal of the American Society of Clinical Oncology 34, no. 18 (June 2016): 2098-2106. Full Text
  - Sonpavde, G, Pond, GR, Templeton, AJ, Fandi, A, Tombal, B, Rosenthal, M, Armstrong, AJ, and Petrylak, DP. "Association Between RECIST Changes and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Receiving Docetaxel." European urology 69, no. 6 (June 2016): 980-983. Full Text
  - Zhang, T, Boominathan, R, Foulk, B, Rao, C, Kemeny, G, Strickler, JH, Abbruzzese, JL, Harrison, MR, Hsu, DS, Healy, P, Li, J, Pi, C, Prendergast, KM, Hobbs, C, Gemberling, S, George, DJ, Hurwitz, HI, Connelly, M, Garcia-Blanco, MA, and Armstrong, AJ. "Development of a Novel c-MET-Based CTC Detection Platform." Mol Cancer Res 14, no. 6 (June 2016): 539-547. Full Text Open Access Copy Link to Item
  - Halabi, S, Kelly, WK, Ma, H, Zhou, H, Solomon, NC, Fizazi, K, Tangen, CM, Rosenthal, M, Petrylak, DP, Hussain, M, Vogelzang, NJ, Thompson, IM, Chi, KN, de Bono, J, Armstrong, AJ, Eisenberger, MA, Fandi, A, Li, S, Araujo, JC, Logothetis, CJ, Quinn, DI, Morris, MJ, Higano, CS, Tannock, IF, and Small, EJ. "Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer." Journal of clinical oncology : official journal of the American Society of Clinical Oncology 34, no. 14 (May 2016): 1652-1659. Full Text
  - Scher, HI, Morris, MJ, Stadler, WM, Higano, C, Basch, E, Fizazi, K, Antonarakis, ES, Beer, TM, Carducci, MA, Chi, KN, Corn, PG, de Bono, JS, Dreicer, R, George, DJ, Heath, EI, Hussain, M, Kelly, WK, Liu, G, Logothetis, C, Nanus, D, Stein, MN, Rathkopf, DE, Slovin, SF, Ryan, CJ, Sartor, O, Small, EJ, Smith, MR, Sternberg, CN, Taplin, M-E, Wilding, G, Nelson, PS, Schwartz, LH, Halabi, S, Kantoff, PW, Armstrong, AJ, and Prostate Cancer Clinical Trials Working Group 3, . "Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3." Journal of clinical oncology : official journal of the American Society of Clinical Oncology 34, no. 12 (April 2016): 1402-1418. Full Text
  - Armstrong, AJ, Halabi, S, Eisen, T, Broderick, S, Stadler, WM, Jones, RJ, Garcia, JA, Vaishampayan, UN, Picus, J, Hawkins, RE, Hainsworth, JD, Kollmannsberger, CK, Logan, TF, Puzanov, I, Pickering, LM, Ryan, CW, Protheroe, A, Lusk, CM, Oberg, S, and George, DJ. "Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial." The Lancet. Oncology 17, no. 3 (March 2016): 378-388. Full Text
  - Armstrong, AJ, Halabi, S, Healy, P, Lee, WR, Koontz, BF, Moul, JW, Mundy, K, Creel, P, Wood, S, Davis, K, Carducci, MA, Stein, M, Hobbs, C, Reimer, B, Nguyen, M, Anand, M, Bratt, L, Kim, S, Tran, PT, George, DJ, and Tr, DDPCC. "A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy in men with PSA recurrent prostate cancer after radical prostatectomy." PROSTATE CANCER AND PROSTATIC DISEASES 19, no. 1 (March 2016): 100-106. Full Text Link to Item
  - Armstrong, AJ, Healy, P, Halabi, S, Vollmer, R, Lark, A, Kemeny, G, Ware, K, and Freedland, SJ. "Evaluation of an epithelial plasticity biomarker panel in men with localized prostate cancer." Prostate cancer and prostatic diseases 19, no. 1 (March 2016): 40-45. Full Text Open Access Copy
  - Graff, JN, Baciarello, G, Armstrong, AJ, Higano, CS, Iversen, P, Flaig, TW, Forer, D, Parli, T, Phung, D, Tombal, B, Beer, TM, and Sternberg, CN. "Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL." Annals of oncology : official journal of the European Society for Medical Oncology 27, no. 2 (February 2016): 286-294. Full Text
  - Mehta, AR, and Armstrong, AJ. "Tasquinimod in the treatment of castrate-resistant prostate cancer - current status and future prospects." Therapeutic advances in urology 8, no. 1 (February 2016): 9-18. (Review) Full Text
  - Tay, KJ, Moul, JW, and Armstrong, AJ. "Management of Prostate Cancer in the Elderly." Clinics in geriatric medicine 32, no. 1 (February 2016): 113-132. (Review) Full Text
  - Mohler, JL, Armstrong, AJ, Bahnson, RR, D'Amico, AV, Davis, BJ, Eastham, JA, Enke, CA, Farrington, TA, Higano, CS, Horwitz, EM, Hurwitz, M, Kane, CJ, Kawachi, MH, Kuettel, M, Lee, RJ, Meeks, JJ, Penson, DF, Plimack, ER, Pow-Sang, JM, Raben, D, Richey, S, III, RM, Rosenfeld, S, Schaeffer, E, Skolarus, TA, Small, EJ, Sonpavde, G, Srinivas, S, Strope, SA, Tward, J, Shead, DA, and Freedman-Cass, DA. "Prostate Cancer, Version 1.2016 Featured Updates to the NCCN Guidelines." JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK 14, no. 1 (January 2016): 19-30. Full Text Link to Item
  - Mohler, JL, Armstrong, AJ, Bahnson, RR, D'Amico, AV, Davis, BJ, Eastham, JA, Enke, CA, Farrington, TA, Higano, CS, Horwitz, EM, Hurwitz, M, Kane, CJ, Kawachi, MH, Kuettel, M, Lee, RJ, Meeks, JJ, Penson, DF, Plimack, ER, Pow-Sang, JM, Raben, D, Richey, S, Roach, M, Rosenfeld, S, Schaeffer, E, Skolarus, TA, Small, EJ, Sonpavde, G, Srinivas, S, Strope, SA, Tward, J, Shead, DA, and Freedman-Cass, DA. "Prostate Cancer, Version 1.2016." Journal of the National Comprehensive Cancer Network : JNCCN 14, no. 1 (January 2016): 19-30. Full Text
  - Zhang, T, and Armstrong, AJ. "Clinical Utility of Circulating Tumor Cells in Advanced Prostate Cancer." Current oncology reports 18, no. 1 (January 2016): 3-. (Review) Full Text
  - Zhang, T, and Armstrong, AJ. "Docetaxel Resistance in Prostate Cancer: Taking It Up a Notch." Clinical cancer research : an official journal of the American Association for Cancer Research 21, no. 20 (October 2015): 4505-4507. Full Text Open Access Copy
  - Hussain, M, Rathkopf, D, Liu, G, Armstrong, A, Kelly, WK, Ferrari, A, Hainsworth, J, Joshi, A, Hozak, RR, Yang, L, Schwartz, JD, and Higano, CS. "A randomised non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancer." European journal of cancer (Oxford, England : 1990) 51, no. 13 (September 2015): 1714-1724. Full Text
  - Kanesvaran, R, Watt, K, Turnbull, JD, Armstrong, AJ, Wolkowiez, MC, and George, DJ. "A Single-Arm Phase 1b Study of Everolimus and Sunitinib in Patients With Advanced Renal Cell Carcinoma." Clinical genitourinary cancer 13, no. 4 (August 2015): 319-327. Full Text
  - Zhang, T, Dhawan, MS, Healy, P, George, DJ, Harrison, MR, Oldan, J, Chin, B, and Armstrong, AJ. "Exploring the Clinical Benefit of Docetaxel or Enzalutamide After Disease Progression During Abiraterone Acetate and Prednisone Treatment in Men With Metastatic Castration-Resistant Prostate Cancer." Clin Genitourin Cancer 13, no. 4 (August 2015): 392-399. Full Text Link to Item
  - Armstrong, AJ. "Docetaxel for advanced prostate cancer: how early to start?." The Lancet. Oncology 16, no. 7 (July 2015): 741-742. Full Text
  - Sonpavde, G, Wang, CG, Galsky, MD, Oh, WK, and Armstrong, AJ. "Cytotoxic chemotherapy in the contemporary management of metastatic castration-resistant prostate cancer (mCRPC)." BJU international 116, no. 1 (July 2015): 17-29. (Review) Full Text
  - Davis, K, Wood, S, Dill, E, Fesko, Y, Bitting, RL, Harrison, MR, Armstrong, AJ, Moul, JW, and George, DJ. "Optimizing the efficiency and quality of sipuleucel-T delivery in an academic institution." Clin J Oncol Nurs 19, no. 3 (June 2015): 297-303. Full Text Link to Item
  - Somarelli, JA, Boss, M-K, Epstein, JI, Armstrong, AJ, and Garcia-Blanco, MA. "Carcinosarcomas: tumors in transition?." Histology and histopathology 30, no. 6 (June 2015): 673-687. (Review) Full Text
  - Stover, JT, Moore, RA, Davis, K, Harrison, MR, and Armstrong, AJ. "Reversal of PSA progression on abiraterone acetate through the administration with food in men with metastatic castration-resistant prostate cancer." Prostate cancer and prostatic diseases 18, no. 2 (June 2015): 161-166. Full Text
  - Armstrong, AJ. "New treatment options in castration-resistant prostate cancer." Journal of the National Comprehensive Cancer Network : JNCCN 13, no. 5 Suppl (May 2015): 690-693. Full Text
  - Armstrong, AJ. "New Treatment Options in Castration-Resistant Prostate Cancer." JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK 13, no. 5.5 (May 2015): 690-693. Full Text Link to Item
  - Li, J, and Armstrong, AJ. "Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Radium-223 is the preferred therapy in bone-predominant symptomatic metastatic castration-resistant prostate cancer." Clinical advances in hematology & oncology : H&O 13, no. 5 (May 2015): 293-298.
  - Armstrong, AJ, and Halabi, S. "Making progress on progression in metastatic prostate cancer." Journal of clinical oncology : official journal of the American Society of Clinical Oncology 33, no. 12 (April 2015): 1322-1324. Full Text
  - Bitting, RL, Healy, P, Halabi, S, George, DJ, Goodin, M, and Armstrong, AJ. "Clinical phenotypes associated with circulating tumor cell enumeration in metastatic castration-resistant prostate cancer." Urologic oncology 33, no. 3 (March 2015): 110.e1-110.e9. Full Text
  - Bitting, RL, Healy, P, Halabi, S, George, DJ, Goodin, M, and Armstrong, AJ. "Clinical phenotypes associated with circulating tumor cell enumeration in metastatic castration-resistant prostate cancer." Urologic Oncology: Seminars and Original Investigations 33, no. 3 (March 1, 2015): 110.e1-110.e9. Full Text
  - Harrison, MR, and Armstrong, AJ. "Burden of disease matters when it comes to systemic therapy for prostate cancer." Eur Urol 67, no. 3 (March 2015): 448-450. Full Text Link to Item
  - Harrison, MR, and Armstrong, AJ. "Burden of disease matters when it comes to systemic therapy for prostate cancer." European Urology 67, no. 3 (March 1, 2015): 448-450. Full Text
  - Zhang, T, Zhu, J, George, DJ, and Armstrong, AJ. "Enzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancer." Expert opinion on pharmacotherapy 16, no. 4 (March 2015): 473-485. (Review) Full Text
  - Li, J, Gregory, SG, Garcia-Blanco, MA, and Armstrong, AJ. "Using circulating tumor cells to inform on prostate cancer biology and clinical utility." Critical reviews in clinical laboratory sciences 52, no. 4 (January 2015): 191-210. (Review) Full Text
  - Shuch, B, Amin, A, Armstrong, AJ, Eble, JN, Ficarra, V, Lopez-Beltran, A, Martignoni, G, Rini, BI, and Kutikov, A. "Understanding pathologic variants of renal cell carcinoma: distilling therapeutic opportunities from biologic complexity." European urology 67, no. 1 (January 2015): 85-97. (Review) Full Text
  - Shuch, B, Amin, A, Armstrong, AJ, Eble, JN, Ficarra, V, Lopez-Beltran, A, Martignoni, G, Rini, BI, and Kutikov, A. "Understanding pathologic variants of renal cell carcinoma: Distilling therapeutic opportunities from biologic complexity." European Urology 67, no. 1 (January 1, 2015): 85-97. Full Text
  - Sonpavde, G, Pond, GR, Armstrong, AJ, Galsky, MD, Leopold, L, Wood, BA, Wang, S-L, Paolini, J, Chen, I, Chow-Maneval, E, Mooney, DJ, Lechuga, M, Smith, MR, and Michaelson, MD. "Radiographic progression by Prostate Cancer Working Group (PCWG)-2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostate cancer." BJU international 114, no. 6b (December 2014): E25-E31. Full Text
  - Stewart, SB, Moul, JW, Polascik, TJ, Koontz, BF, Robertson, CN, Freedland, SJ, George, DJ, Lee, WR, Armstrong, AJ, and Bañez, LL. "Does the multidisciplinary approach improve oncological outcomes in men undergoing surgical treatment for prostate cancer?." International journal of urology : official journal of the Japanese Urological Association 21, no. 12 (December 2014): 1215-1219. Full Text
  - Armstrong, AJ, Kaboteh, R, Carducci, MA, Damber, J-E, Stadler, WM, Hansen, M, Edenbrandt, L, Forsberg, G, Nordle, Ö, Pili, R, and Morris, MJ. "Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC)." Urologic oncology 32, no. 8 (November 2014): 1308-1316. Full Text
  - Armstrong, AJ. "In hormone-naive metastatic prostate cancer, should all patients now receive docetaxel? No, not yet." Oncology (Williston Park, N.Y.) 28, no. 10 (October 2014): 881-883.
  - Armstrong, AJ. "In hormone-naive metastatic prostate cancer, should all patients now receive docetaxel? No, not yet." Oncology (Williston Park, N.Y.) 28, no. 10 (October 1, 2014): 883-.
  - Sonpavde, G, Pond, GR, Armstrong, AJ, Clarke, SJ, Vardy, JL, Templeton, AJ, Wang, S-L, Paolini, J, Chen, I, Chow-Maneval, E, Lechuga, M, Smith, MR, and Michaelson, MD. "Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer." Clinical genitourinary cancer 12, no. 5 (October 2014): 317-324. Full Text
  - Bitting, RL, Schaeffer, D, Somarelli, JA, Garcia-Blanco, MA, and Armstrong, AJ. "The role of epithelial plasticity in prostate cancer dissemination and treatment resistance." Cancer Metastasis Rev 33, no. 2-3 (September 2014): 441-468. (Review) Full Text Link to Item
  - Halabi, S, Zhou, H, Small, EJ, Solomon, NC, Armstrong, AJ, Shen, L, Oudard, S, Sartor, O, and de Bono, JS. "795PA PROGNOSTIC MODEL FOR PREDICTING RADIOGRAPHIC PROGRESSION- FREE SURVIVAL (RPFS) IN METASTATIC CASTRATE-RESISTANT PROSTATE CANCER MEN TREATED WITH SECOND-LINE CHEMOTHERAPY." Annals of oncology : official journal of the European Society for Medical Oncology 25, no. suppl_4 (September 2014): iv276-.
  - Bitting, RL, Healy, P, Creel, PA, Turnbull, J, Morris, K, Wood, SY, Hurwitz, HI, Starr, MD, Nixon, AB, Armstrong, AJ, and George, DJ. "A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinoma." Clinical genitourinary cancer 12, no. 4 (August 2014): 241-250. Full Text
  - Ware, KE, Garcia-Blanco, MA, Armstrong, AJ, and Dehm, SM. "Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer." Endocrine-related cancer 21, no. 4 (August 2014): T87-T103. (Review) Full Text
  - Beer, TM, Armstrong, AJ, Rathkopf, DE, Loriot, Y, Sternberg, CN, Higano, CS, Iversen, P, Bhattacharya, S, Carles, J, Chowdhury, S, Davis, ID, de Bono, JS, Evans, CP, Fizazi, K, Joshua, AM, Kim, C-S, Kimura, G, Mainwaring, P, Mansbach, H, Miller, K, Noonberg, SB, Perabo, F, Phung, D, Saad, F, Scher, HI, Taplin, M-E, Venner, PM, Tombal, B, and PREVAIL Investigators, . "Enzalutamide in metastatic prostate cancer before chemotherapy." The New England journal of medicine 371, no. 5 (July 2014): 424-433. Full Text
  - Aggarwal, R, Zhang, T, Small, EJ, and Armstrong, AJ. "Neuroendocrine prostate cancer: subtypes, biology, and clinical outcomes." Journal of the National Comprehensive Cancer Network : JNCCN 12, no. 5 (May 2014): 719-726. (Review) Full Text
  - Mohler, JL, Kantoff, PW, Armstrong, AJ, Bahnson, RR, Cohen, M, D'Amico, AV, Eastham, JA, Enke, CA, Farrington, TA, Higano, CS, Horwitz, EM, Kane, CJ, Kawachi, MH, Kuettel, M, Kuzel, TM, Lee, RJ, Malcolm, AW, Miller, D, Plimack, ER, Pow-Sang, JM, Raben, D, Richey, S, Roach, M, Rohren, E, Rosenfeld, S, Schaeffer, E, Small, EJ, Sonpavde, G, Srinivas, S, Stein, C, Strope, SA, Tward, J, Shead, DA, Ho, M, and National Comprehensive Cancer Network, . "Prostate cancer, version 2.2014." Journal of the National Comprehensive Cancer Network : JNCCN 12, no. 5 (May 2014): 686-718. Full Text
  - Younis, IR, George, DJ, McManus, TJ, Hurwitz, H, Creel, P, Armstrong, AJ, Yu, JJ, Bacon, K, Hobbs, G, Peer, CJ, and Petros, WP. "Clinical pharmacology of an atrasentan and docetaxel regimen in men with hormone-refractory prostate cancer." Cancer chemotherapy and pharmacology 73, no. 5 (May 2014): 991-997. Full Text
  - Armstrong, AJ. "New treatments for men with castration-resistant prostate cancer: Can we move from small steps to giant leaps?." European Urology 65, no. 2 (February 1, 2014): 300-302. Full Text
  - Armstrong, AJ. "Biomarkers in castration-resistant prostate cancer." Clinical advances in hematology & oncology : H&O 12, no. 2 (February 2014): 115-118.
  - Armstrong, AJ. "Biomarkers in castration-resistant prostate cancer." Clinical Advances in Hematology and Oncology 12, no. 2 (February 1, 2014): 115-118.
  - Armstrong, AJ. "New treatments for men with castration-resistant prostate cancer: can we move from small steps to giant leaps?." Eur Urol 65, no. 2 (February 2014): 300-302. Full Text Link to Item
  - Armstrong, AJ, Kaboteh, R, Carducci, MA, Damber, JE, Stadler, WM, Hansen, M, Edenbrandt, L, Forsberg, G, Nordle, Ö, Pili, R, and Morris, MJ. "Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC)1A.J.A. and R.K. contributed equally to this work." Urologic Oncology: Seminars and Original Investigations 32, no. 8 (January 1, 2014): 1308-1316. Full Text
  - Bitting, RL, Healy, P, Creel, PA, Turnbull, J, Morris, K, Wood, SY, Hurwitz, HI, Starr, MD, Nixon, AB, Armstrong, AJ, and George, DJ. "A phase Ib study of combined VEGFR and mTOR inhibition with Vatalanib and everolimus in patients with advanced renal cell carcinoma." Clinical Genitourinary Cancer 12, no. 4 (January 1, 2014): 241-250. Full Text
  - Bitting, RL, Schaeffer, D, Somarelli, JA, Garcia-Blanco, MA, and Armstrong, AJ. "The role of epithelial plasticity in prostate cancer dissemination and treatment resistance." Cancer and Metastasis Reviews 33, no. 2-3 (January 1, 2014): 441-468. Full Text
  - Mohler, JL, Kantoff, PW, Armstrong, AJ, Bahnson, RR, Cohen, M, D'Amico, AV, Eastham, JA, Enke, CA, Farrington, TA, Higano, CS, Horwitz, EM, Kane, CJ, Kawachi, MH, Kuettel, M, Kuzel, TM, Lee, RJ, Malcolm, AW, Miller, D, Plimack, ER, Pow-Sang, JM, Raben, D, Richey, S, Roach, M, Rohren, E, Rosenfeld, S, Schaeffer, E, Small, EJ, Sonpavde, G, Srinivas, S, Stein, C, Strope, SA, Tward, J, Shead, DA, and Ho, M. "Prostate Cancer,Version 2.2014 Clinical Practice Guidelines in Oncology." JNCCN Journal of the National Comprehensive Cancer Network 12, no. 5 (January 1, 2014): 686-718. (Review)
  - Pond, GR, Sonpavde, G, De Wit, R, Eisenberger, MA, Tannock, IF, and Armstrong, AJ. "The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer." European Urology 65, no. 1 (January 1, 2014): 3-6. Full Text
  - Sonpavde, G, Pond, GR, Armstrong, AJ, Clarke, SJ, Vardy, JL, Templeton, AJ, Wang, SL, Paolini, J, Chen, I, Chow-Maneval, E, Lechuga, M, Smith, MR, and Dror Michaelson, M. "Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer." Clinical Genitourinary Cancer 12, no. 5 (January 1, 2014): 317-324. Full Text
  - Stewart, SB, Moul, JW, Polascik, TJ, Koontz, BF, Robertson, CN, Freedland, SJ, George, DJ, Lee, WR, Armstrong, AJ, and Bañez, LL. "Does the multidisciplinary approach improve oncological outcomes in men undergoing surgical treatment for prostate cancer?." International Journal of Urology 21, no. 12 (January 1, 2014): 1215-1219. Full Text
  - Younis, IR, George, DJ, McManus, TJ, Hurwitz, H, Creel, P, Armstrong, AJ, Yu, JJ, Bacon, K, Hobbs, G, Peer, CJ, and Petros, WP. "Clinical pharmacology of an atrasentan and docetaxel regimen in men with hormone-refractory prostate cancer." Cancer Chemotherapy and Pharmacology 73, no. 5 (January 1, 2014): 991-997. Full Text
  - Armstrong, AJ, Häggman, M, Stadler, WM, Gingrich, JR, Assikis, V, Polikoff, J, Damber, JE, Belkoff, L, Nordle, Ö, Forsberg, G, Carducci, MA, and Pili, R. "Long-term survival and biomarker correlates of tasquinimod efficacy in a multicenter randomized study of men with minimally symptomatic metastatic castration-resistant prostate cancer." Clin Cancer Res 19, no. 24 (December 15, 2013): 6891-6901. Full Text Link to Item
  - Araujo, JC, Trudel, GC, Saad, F, Armstrong, AJ, Yu, EY, Bellmunt, J, Wilding, G, McCaffrey, J, Serrano, SV, Matveev, VB, Efstathiou, E, Oudard, S, Morris, MJ, Sizer, B, Goebell, PJ, Heidenreich, A, de Bono, JS, Begbie, S, Hong, JH, Richardet, E, Gallardo, E, Paliwal, P, Durham, S, Cheng, S, and Logothetis, CJ. "Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): A randomised, double-blind phase 3 trial." The Lancet Oncology 14, no. 13 (December 1, 2013): 1307-1316. Full Text
  - Armstrong, AJ, Shen, T, Halabi, S, Kemeny, G, Bitting, RL, Kartcheske, P, Embree, E, Morris, K, Winters, C, Jaffe, T, Fleming, M, and George, DJ. "A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer." Clinical Genitourinary Cancer 11, no. 4 (December 1, 2013): 397-406. Full Text
  - Armstrong, AJ, Shen, T, Halabi, S, Kemeny, G, Bitting, RL, Kartcheske, P, Embree, E, Morris, K, Winters, C, Jaffe, T, Fleming, M, and George, DJ. "A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer." Clin Genitourin Cancer 11, no. 4 (December 2013): 397-406. Full Text Link to Item
  - Bitting, RL, Boominathan, R, Rao, C, Kemeny, G, Foulk, B, Garcia-Blanco, MA, Connelly, M, and Armstrong, AJ. "Development of a method to isolate circulating tumor cells using mesenchymal-based capture." Methods 64, no. 2 (December 1, 2013): 129-136. Full Text
  - Bitting, RL, Boominathan, R, Rao, C, Kemeny, G, Foulk, B, Garcia-Blanco, MA, Connelly, M, and Armstrong, AJ. "Development of a method to isolate circulating tumor cells using mesenchymal-based capture." Methods 64, no. 2 (December 1, 2013): 129-136. Full Text Link to Item
  - Mohler, JL, Kantoff, PW, Armstrong, AJ, Bahnson, RR, Cohen, M, D'Amico, AV, Eastham, JA, Enke, CA, Farrington, TA, Higano, CS, Horwitz, EM, Kawachi, MH, Kuettel, M, Lee, RJ, Macvicar, GR, Malcolm, AW, Miller, D, Plimack, ER, Pow-Sang, JM, Richey, S, Roach, M, Rohren, E, Rosenfeld, S, Small, EJ, Srinivas, S, Stein, C, Strope, SA, Tward, J, Walsh, PC, Shead, DA, Ho, M, and National comprehensive cancer network, . "Prostate cancer, version 1.2014." Journal of the National Comprehensive Cancer Network : JNCCN 11, no. 12 (December 2013): 1471-1479. Full Text
  - Schweizer, MT, Lin, J, Blackford, A, Bardia, A, King, S, Armstrong, AJ, Rudek, MA, Yegnasubramanian, S, and Carducci, MA. "Pharmacodynamic study of disulfiram in men with non-metastatic recurrent prostate cancer." Prostate Cancer and Prostatic Diseases 16, no. 4 (December 1, 2013): 357-361. Full Text
  - Stoyanova, T, Cooper, AR, Drake, JM, Liu, X, Armstrong, AJ, Pienta, KJ, Zhang, H, Kohn, DB, Huang, J, Witte, ON, and Goldstein, AS. "Prostate cancer originating in basal cells progresses to adenocarcinoma propagated by luminal-like cells." Proceedings of the National Academy of Sciences of the United States of America 110, no. 50 (December 2013): 20111-20116. Full Text
  - Halabi, S, Lin, C-Y, Small, EJ, Armstrong, AJ, Kaplan, EB, Petrylak, D, Sternberg, CN, Shen, L, Oudard, S, de Bono, J, and Sartor, O. "Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy." J Natl Cancer Inst 105, no. 22 (November 20, 2013): 1729-1737. Full Text Link to Item
  - Halabi, S, Armstrong, AJ, Sartor, O, de Bono, J, Kaplan, E, Lin, C-Y, Solomon, NC, and Small, EJ. "Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapy." J Clin Oncol 31, no. 31 (November 1, 2013): 3944-3950. Full Text Link to Item
  - Pond, GR, Armstrong, AJ, Galsky, MD, Wood, BA, Leopold, L, and Sonpavde, G. "Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: Implications for prior therapy in clinical trials." Urologic Oncology: Seminars and Original Investigations 31, no. 8 (November 1, 2013): 1457-1463. Full Text
  - Zhang, T, and Armstrong, AJ. "Clinical phenotypes of castration-resistant prostate cancer." Clinical advances in hematology & oncology : H&O 11, no. 11 (November 2013): 707-718. (Review)
  - Peppercorn, J, Armstrong, A, Zaas, DW, and George, D. "Rationing in urologic oncology: lessons from sipuleucel-T for advanced prostate cancer." Urol Oncol 31, no. 7 (October 2013): 1079-1084. Full Text Link to Item
  - George, DJ, Armstrong, AJ, and Harrison, MR. "Highlights in advanced prostate cancer from the 2013 American Urological Association Annual Meeting and the 2013 American Society of Clinical Oncology Annual Meeting: commentary." Clin Adv Hematol Oncol 11 Suppl 14, no. 9 (September 2013): 16-22. Link to Item
  - Noonan, KL, North, S, Bitting, RL, Armstrong, AJ, Ellard, SL, and Chi, KN. "Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide." Ann Oncol 24, no. 7 (July 2013): 1802-1807. Full Text Link to Item
  - Bitting, RL, and Armstrong, AJ. "Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer. (Published online)" Endocr Relat Cancer 20, no. 3 (June 2013): R83-R99. (Review) Full Text Link to Item
  - Armstrong, AJ, George, DJ, and Halabi, S. "Reply to M A Khattak et al." J Clin Oncol 31, no. 7 (March 1, 2013): 972-973. (Letter) Full Text Link to Item
  - Armstrong, AJ, George, DJ, and Halabi, S. "Prognostic and Predictive Markers in Metastatic Renal Cell Carcinoma Reply." JOURNAL OF CLINICAL ONCOLOGY 31, no. 7 (March 1, 2013): 972-973. Full Text Link to Item
  - Clarke, JM, and Armstrong, AJ. "Novel therapies for the treatment of advanced prostate cancer." Curr Treat Options Oncol 14, no. 1 (March 2013): 109-126. (Review) Full Text Link to Item
  - Turnbull, JD, Cobert, J, Jaffe, T, Harrison, MR, George, DJ, and Armstrong, AJ. "Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors." Clin Genitourin Cancer 11, no. 1 (March 2013): 45-50. Full Text Link to Item
  - Bardia, A, Blackford, AL, Lin, J, Armstrong, AJ, King, S, Rudek, MA, Yegnasubramanian, ST, and Carducci, MA. "A prostate cancer clinical trials consortium trial of disulfiram (D) in men with nonmetastatic recurrent prostate cancer (PCa)." Journal of clinical oncology : official journal of the American Society of Clinical Oncology 31, no. 6_suppl (February 2013): 219-.
  - Fizazi, K, Saad, F, Chi, KN, Taplin, ME, Sternberg, CN, Armstrong, AJ, Hirmand, M, Forer, D, and De Bono, JS. "Impact of on-study corticosteroid use on efficacy and safety in the phase III AFFIRM study of enzalutamide (ENZA), an androgen receptor inhibitor." Journal of clinical oncology : official journal of the American Society of Clinical Oncology 31, no. 6_suppl (February 2013): 6-.
  - Lin, CY, Small, EJ, Armstrong, AJ, Kaplan, EB, Petrylak, DP, Sternberg, CN, Shen, L, Oudard, S, De Bono, JS, and Sartor, AO. "A model for predicting overall survival in men with metastatic castrate-resistant prostate cancer (CRPC) for whom first-line chemotherapy failed." Journal of clinical oncology : official journal of the American Society of Clinical Oncology 31, no. 6_suppl (February 2013): 24-.
  - Trudel, GC, Saad, F, Armstrong, AJ, Yu, EY, Bellmunt, J, Wilding, G, McCaffrey, J, Serrano, SV, Matveev, V, Efstathiou, E, Oudard, S, Morris, MJ, Sizer, B, Goebell, PJ, De Bono, JS, Paliwal, P, Durham, S, Cheng, S, and Logothetis, C. "Overall survival (OS) and safety of dasatinib/docetaxel versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): Results from the randomized phase III READY trial." Journal of clinical oncology : official journal of the American Society of Clinical Oncology 31, no. 6_suppl (February 2013): LBA8-.
  - Araujo, JC, Trudel, GC, Saad, F, Armstrong, AJ, Yu, EY, Bellmunt, J, Wilding, G, McCaffrey, J, Serrano, SV, Matveev, VB, Efstathiou, E, Oudard, S, Morris, MJ, Sizer, B, Goebell, PJ, Heidenreich, A, de Bono, JS, Begbie, S, Hong, JH, Richardet, E, Gallardo, E, Paliwal, P, Durham, S, Cheng, S, and Logothetis, CJ. "Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial." The Lancet Oncology (2013).
  - Bitting, RL, and Armstrong, AJ. "Potential predictive biomarkers for individualizing treatment for men with castration-resistant prostate cancer." Cancer J 19, no. 1 (January 2013): 25-33. (Review) Full Text Link to Item
  - Harrison, MR, Wong, TZ, Armstrong, AJ, and George, DJ. "Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease." Cancer Manag Res 5 (2013): 1-14. Full Text Link to Item
  - Peppercorn, J, Armstrong, A, Zaas, DW, and George, D. "Rationing in urologic oncology: Lessons from sipuleucel-T for advanced prostate cancer." Urologic Oncology: Seminars and Original Investigations 31, no. 7 (2013): 1079-1084. Full Text
  - Pond, GR, Sonpavde, G, Wit, RD, Eisenberger, MA, Tannock, IF, and Armstrong, AJ. "The Prognostic Importance of Metastatic Site in Men with Metastatic Castration-resistant Prostate Cancer." European Urology (2013). Full Text
  - Saylor, PJ, Armstrong, AJ, Fizazi, K, Freedland, S, Saad, F, Smith, MR, Tombal, B, and Pienta, K. "New and emerging therapies for bone metastases in genitourinary cancers." European Urology 63, no. 2 (2013): 309-320. Full Text
  - Schweizer, MT, Lin, J, Blackford, A, Bardia, A, King, S, Armstrong, AJ, Rudek, MA, Yegnasubramanian, S, and Carducci, MA. "Pharmacodynamic study of disulfiram in men with non-metastatic recurrent prostate cancer." Prostate Cancer and Prostatic Diseases (2013). Full Text
  - Whang, YE, Armstrong, AJ, Rathmell, WK, Godley, PA, Kim, WY, Pruthi, RS, Wallen, EM, Crane, JM, Moore, DT, Grigson, G, Morris, K, Watkins, CP, and George, DJ. "A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer." Urol Oncol 31, no. 1 (January 2013): 82-86. Full Text Link to Item
  - Whang, YE, Armstrong, AJ, Rathmell, WK, Godley, PA, Kim, WY, Pruthi, RS, Wallen, EM, Crane, JM, Moore, DT, Grigson, G, Morris, K, Watkins, CP, and George, DJ. "A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer." Urologic Oncology: Seminars and Original Investigations 31, no. 1 (2013): 82-86. Full Text
  - Pond, GR, Armstrong, AJ, Wood, BA, Leopold, L, Galsky, MD, and Sonpavde, G. "Ability of C-reactive protein to complement multiple prognostic classifiers in men with metastatic castration resistant prostate cancer receiving docetaxel-based chemotherapy." BJU Int 110, no. 11 Pt B (December 2012): E461-E468. Full Text Link to Item
  - Armstrong, AJ, George, DJ, and Halabi, S. "Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin." J Clin Oncol 30, no. 27 (September 20, 2012): 3402-3407. Full Text Link to Item
  - Sonpavde, G, Pond, GR, Berry, WR, de Wit, R, Armstrong, AJ, Eisenberger, MA, and Tannock, IF. "Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy." Urol Oncol 30, no. 5 (September 2012): 607-613. Full Text Link to Item
  - Armstrong, AJ. "The STAMPEDE trial and celecoxib: how to adapt?." Lancet Oncol 13, no. 5 (May 2012): 443-445. Full Text Link to Item
  - Sandilos, JK, Chiu, Y-H, Chekeni, FB, Armstrong, AJ, Walk, SF, Ravichandran, KS, and Bayliss, DA. "Pannexin 1, an ATP release channel, is activated by caspase cleavage of its pore-associated C-terminal autoinhibitory region." J Biol Chem 287, no. 14 (March 30, 2012): 11303-11311. Full Text Link to Item
  - Armstrong, AJ, Eisenberger, MA, Halabi, S, Oudard, S, Nanus, DM, Petrylak, DP, Sartor, AO, and Scher, HI. "Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer." Eur Urol 61, no. 3 (March 2012): 549-559. (Review) Full Text Link to Item
  - Armstrong, AJ, Turnbull, JD, Cobert, J, Jaffe, T, Harrison, MR, and George, DJ. "Activity of single-agent bevacizumab (B) in patients with metastatic renal cell carcinoma (RCC) previously treated with VEGF- and mTOR-based therapies." J Clin Oncol 30, no. 5_suppl (February 10, 2012): 435-. Full Text Link to Item
  - Hussain, M, Rathkopf, DE, Liu, G, Armstrong, AJ, Kelly, WK, Ferrari, AC, Hainsworth, JD, Yang, L, Schwartz, JD, and Higano, CS. "A phase II randomized study of cixutumumab (IMC-A12: CIX) or ramucirumab (IMC-1121B: RAM) plus mitoxantrone (M) and prednisone (P) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) following disease progression (PD) on docetaxel (DCT) therapy." JOURNAL OF CLINICAL ONCOLOGY 30, no. 5 (February 10, 2012). Full Text Link to Item
  - Pond, GR, Armstrong, AJ, Wood, BA, Leopold, LH, Galsky, MD, and Sonpavde, G. "Efficacy of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer (mCRPC) exposed to prior ketoconazole (KC)." JOURNAL OF CLINICAL ONCOLOGY 30, no. 5 (February 10, 2012). Full Text Link to Item
  - Armstrong, AJ, Gingrich, JR, Haggman, M, Stadler, WM, Damber, JE, Belkoff, L, Clark, R, Brosman, S, Nordle, O, Forsberg, G, Carducci, MA, and Pili, R. "Long term safety and efficacy in a randomized multicenter international phase II study of tasquinimod in chemotherapy naive patients with metastatic castrate-resistant prostate cancer." EUROPEAN UROLOGY SUPPLEMENTS 11, no. 1 (February 2012): E126-U515. Link to Item
  - Armstrong, AJ, Turnbull, JD, Cobert, J, Jaffe, T, Harrison, MR, and George, DJ. "Activity of single-agent bevacizumab (B) in patients with metastatic renal cell carcinoma (RCC) previously treated with VEGF- and mTOR-based therapies." Journal of clinical oncology : official journal of the American Society of Clinical Oncology 30, no. 5_suppl (February 2012): 435-.
  - Armstrong, AJ, Turnbull, JD, Cobert, J, Jaffe, T, Harrison, MR, and George, DJ. "Activity of single-agent bevacizumab (B) in patients with metastatic renal cell carcinoma (RCC) previously treated with VEGF- and mTOR-based therapies." Journal of clinical oncology : official journal of the American Society of Clinical Oncology 30, no. 5_suppl (February 2012): 435-.
  - Hussain, M, Rathkopf, DE, Liu, G, Armstrong, AJ, Kelly, WK, Ferrari, AC, Hainsworth, JD, Yang, L, Schwartz, JD, and Higano, CS. "A phase II randomized study of cixutumumab (IMC-A12: CIX) or ramucirumab (IMC-1121B: RAM) plus mitoxantrone (M) and prednisone (P) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) following disease progression (PD) on docetaxel (DCT) therapy." Journal of clinical oncology : official journal of the American Society of Clinical Oncology 30, no. 5_suppl (February 2012): 97-.
  - Hussain, M, Rathkopf, DE, Liu, G, Armstrong, AJ, Kelly, WK, Ferrari, AC, Hainsworth, JD, Yang, L, Schwartz, JD, and Higano, CS. "A phase II randomized study of cixutumumab (IMC-A12: CIX) or ramucirumab (IMC-1121B: RAM) plus mitoxantrone (M) and prednisone (P) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) following disease progression (PD) on docetaxel (DCT) therapy." Journal of clinical oncology : official journal of the American Society of Clinical Oncology 30, no. 5_suppl (February 2012): 97-.
  - Pond, GR, Armstrong, AJ, Wood, BA, Brookes, M, Leopold, L, Berry, WR, de Wit, R, Eisenberger, MA, Tannock, IF, and Sonpavde, G. "Evaluating the value of number of cycles of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer." Eur Urol 61, no. 2 (February 2012): 363-369. Full Text Link to Item
  - Pond, GR, Armstrong, AJ, Wood, BA, Leopold, LH, Galsky, MD, and Sonpavde, G. "Efficacy of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer (mCRPC) exposed to prior ketoconazole (KC)." Journal of clinical oncology : official journal of the American Society of Clinical Oncology 30, no. 5_suppl (February 2012): 204-.
  - Pond, GR, Armstrong, AJ, Wood, BA, Leopold, LH, Galsky, MD, and Sonpavde, G. "Efficacy of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer (mCRPC) exposed to prior ketoconazole (KC)." Journal of clinical oncology : official journal of the American Society of Clinical Oncology 30, no. 5_suppl (February 2012): 204-.
  - Araujo, JC, Mathew, P, Armstrong, AJ, Braud, EL, Posadas, E, Lonberg, M, Gallick, GE, Trudel, GC, Paliwal, P, Agrawal, S, and Logothetis, CJ. "Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study." Cancer 118, no. 1 (January 1, 2012): 63-71. Full Text Link to Item
  - Armstrong, AJ, Moul, JW, and George, DJ. "What to order from the prostate cancer treatment menu?." Oncology 26, no. 1 (2012).
  - Armstrong, AJ. "Where does abiraterone fit into the metastatic prostate cancer treatment algorithm?." Community Oncology 9, no. 8 (2012): 238-239. Full Text
  - Bitting, RL, and Armstrong, AJ. "Prognostic, predictive, and surrogate factors for individualizing treatment for men with castration-resistant prostate cancer." American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Meeting (January 2012): 292-297. Full Text
  - Mohler, JL, Armstrong, AJ, Bahnson, RR, Boston, B, Busby, JE, D'Amico, AV, Eastham, JA, Enke, CA, Farrington, T, Higano, CS, Horwitz, EM, Kantoff, PW, Kawachi, MH, Kuettel, M, Lee, RJ, MacVicar, GR, Malcolm, AW, Miller, D, Plimack, ER, Pow-Sang, JM, III, MR, Rohren, E, Rosenfeld, S, Srinivas, S, Strope, SA, Tward, J, Twardowski, P, Walsh, PC, Ho, M, and Shead, DA. "Prostate cancer, version 3.2012: Featured updates to the NCCN Guidelines." JNCCN Journal of the National Comprehensive Cancer Network 10, no. 9 (2012): 1081-1087.
  - Pond, GR, Armstrong, AJ, Galsky, MD, Wood, BA, Leopold, L, and Sonpavde, G. "Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: Implications for prior therapy in clinical trials." Urologic Oncology: Seminars and Original Investigations (2012). Full Text
  - Pond, GR, Armstrong, AJ, Wood, BA, Leopold, L, Galsky, MD, and Sonpavde, G. "Ability of C-reactive protein to complement multiple prognostic classifiers in men with metastatic castration resistant prostate cancer receiving docetaxel-based chemotherapy." BJU International 110, no. 11 B (2012): E461-E468. Full Text
  - Saylor, PJ, Armstrong, AJ, Fizazi, K, Freedland, S, Saad, F, Smith, MR, Tombal, B, and Pienta, K. "New and Emerging Therapies for Bone Metastases in Genitourinary Cancers." European Urology (2012). Full Text
  - Scher, HI, Fizazi, K, Saad, F, Taplin, M-E, Sternberg, CN, Miller, K, Wit, RD, Mulders, P, Chi, KN, Shore, ND, Armstrong, AJ, Flaig, TW, Fléchon, A, Mainwaring, P, Fleming, M, Hainsworth, JD, Hirmand, M, Selby, B, Seely, L, and Bono, JSD. "Increased survival with enzalutamide in prostate cancer after chemotherapy." New England Journal of Medicine 367, no. 13 (2012): 1187-1197. Full Text
  - Sonpavde, G, Pond, GR, and Armstrong, AJ. "Reply to YiJun Shen and DingWei Ye's letter to the Editor re: Gregory R. Pond, Andrew J. Armstrong, Brian A. Wood, et al. Evaluating the value of number of cycles of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer. Eur Urol 2012;61:363-9." European Urology 61, no. 2 (2012): e4-e5. Full Text
  - Sonpavde, G, and Armstrong, AJ. "Objective evaluation of bone metastases in prostate cancer: To what end?." European Urology 62, no. 1 (2012): 85-87. Full Text
  - Stewart, SB, Bañez, LL, Robertson, CN, Freedland, SJ, Polascik, TJ, Xie, D, Koontz, BF, Vujaskovic, Z, Lee, WR, Armstrong, AJ, Febbo, PG, George, DJ, and Moul, JW. "Utilization trends at a multidisciplinary prostate cancer clinic: initial 5-year experience from the Duke Prostate Center." J Urol 187, no. 1 (January 2012): 103-108. Full Text Link to Item
  - Armstrong, AJ, Ferrari, AC, and Quinn, DI. "The role of surrogate markers in the management of men with metastatic castration-resistant prostate cancer." Clin Adv Hematol Oncol 9, no. 12 Suppl 28 (December 2011): 1-14. (Review) Link to Item
  - Armstrong, AJ. "Epithelial-mesenchymal transition in cancer progression." Clin Adv Hematol Oncol 9, no. 12 (December 2011): 941-943. Link to Item
  - Pili, R, Häggman, M, Stadler, WM, Gingrich, JR, Assikis, VJ, Björk, A, Nordle, O, Forsberg, G, Carducci, MA, and Armstrong, AJ. "Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer." J Clin Oncol 29, no. 30 (October 20, 2011): 4022-4028. Full Text Link to Item
  - Antonarakis, ES, and Armstrong, AJ. "Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer." Prostate Cancer Prostatic Dis 14, no. 3 (September 2011): 192-205. (Review) Full Text Link to Item
  - Antonarakis, ES, and Armstrong, AJ. "Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer." Prostate Cancer Prostatic Dis 14, no. 3 (September 2011): 206-218. (Review) Full Text Link to Item
  - Sonpavde, G, Pond, GR, Berry, WR, de Wit, R, Eisenberger, MA, Tannock, IF, and Armstrong, AJ. "The association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapy." Cancer 117, no. 17 (September 1, 2011): 3963-3971. Full Text Link to Item
  - Armstrong, AJ, Marengo, MS, Oltean, S, Kemeny, G, Bitting, RL, Turnbull, JD, Herold, CI, Marcom, PK, George, DJ, and Garcia-Blanco, MA. "Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers." Mol Cancer Res 9, no. 8 (August 2011): 997-1007. Full Text Link to Item
  - Bitting, RL, Madden, J, and Armstrong, AJ. "Therapy for non-clear cell histologies in renal cancer." Curr Clin Pharmacol 6, no. 3 (August 2011): 169-180. (Review) Link to Item
  - Fleming, MT, Pond, GR, Armstrong, AJ, Wood, BA, Brookes, M, Leopold, LH, Matveev, VB, Burke, JM, Caton, JR, and Sonpavde, G. "Ability of serum alkaline phosphatase (ALP) changes to complement PSA changes and predict survival in men with metastatic castration-resistant prostate cancer (mCRPC) receiving docetaxel and prednisone (DP)." Journal of Clinical Oncology 29, no. 15_suppl (May 20, 2011): e15019-e15019. Full Text
  - Pond, GR, Armstrong, AJ, Wood, BA, Brookes, M, Leopold, LH, Berry, WR, De Wit, R, Eisenberger, MA, Tannock, I, and Sonpavde, G. "Evaluating the value of continuing docetaxel and prednisone (DP) beyond 10 cycles in men with metastatic castration-resistant prostate cancer (mCRPC)." Journal of Clinical Oncology 29, no. 15_suppl (May 20, 2011): 4582-4582. Full Text
  - Fleming, MT, Pond, GR, Armstrong, AJ, Wood, BA, Brookes, M, Leopold, LH, Matveev, VB, Burke, JM, Caton, JR, and Sonpavde, G. "Ability of serum alkaline phosphatase (ALP) changes to complement PSA changes and predict survival in men with metastatic castration-resistant prostate cancer (mCRPC) receiving docetaxel and prednisone (DP)." Journal of clinical oncology : official journal of the American Society of Clinical Oncology 29, no. 15_suppl (May 2011): e15019-.
  - George, DJ, Halabi, S, Zurita, AJ, Creel, P, Mundy, K, Turnbull, JD, Yenser Wood, SE, Armstrong, AJ, Varley, RJ, Madden, J, and Moul, JW. "Investigator-initiated pilot study of sunitinib malate in patients with newly diagnosed prostate cancer prior to prostatectomy: A trial of the DoD/PCF Prostate Cancer Clinical Trials Consortium." Journal of clinical oncology : official journal of the American Society of Clinical Oncology 29, no. 15_suppl (May 2011): 4664-.
  - Pond, GR, Armstrong, AJ, Wood, BA, Brookes, M, Leopold, LH, Berry, WR, De Wit, R, Eisenberger, MA, Tannock, I, and Sonpavde, G. "Evaluating the value of continuing docetaxel and prednisone (DP) beyond 10 cycles in men with metastatic castration-resistant prostate cancer (mCRPC)." Journal of clinical oncology : official journal of the American Society of Clinical Oncology 29, no. 15_suppl (May 2011): 4582-.
  - Armstrong, AJ, Freedland, SJ, and Garcia Blanco, M. "Epithelial-mesenchymal transition in prostate cancer: providing new targets for therapy." Asian journal of andrology 13, no. 2 (March 2011): 179-180. (Academic Article) Full Text
  - Armstrong, AJ, Haggman, M, Stadler, WM, Gingrich, JR, Assikis, VJ, Nordle, O, Forsberg, G, Carducci, MA, and Pili, R. "Phase II study of tasquinimod in chemotherapy-naive patients with metastatic castrate-resistant prostate cancer (CRPC): Safety and efficacy analysis including subgroups." Journal of Clinical Oncology 29, no. 7_suppl (March 2011): 126-126. Full Text
  - Armstrong, AJ, Haggman, M, Stadler, WM, Gingrich, JR, Assikis, VJ, Nordle, O, Forsberg, G, Carducci, MA, and Pili, R. "Phase II study of tasquinimod in chemotherapy-naive patients with metastatic castrate-resistant prostate cancer (CRPC): Safety and efficacy analysis including subgroups." Journal of clinical oncology : official journal of the American Society of Clinical Oncology 29, no. 7_suppl (March 2011): 126-.
  - Pond, GR, Armstrong, AJ, Wood, BA, Brookes, M, Leopold, LH, Burke, JM, Caton, JR, Fleming, MT, and Sonpavde, G. "Assessment of two prognostic risk group methods to predict outcomes with docetaxel-based therapy in men with metastatic castration-resistant prostate cancer (mCRPC)." Journal of Clinical Oncology 29, no. 7_suppl (March 2011): 185-185. Full Text
  - Pond, GR, Armstrong, AJ, Wood, BA, Brookes, M, Leopold, LH, Burke, JM, Caton, JR, Fleming, MT, and Sonpavde, G. "Assessment of two prognostic risk group methods to predict outcomes with docetaxel-based therapy in men with metastatic castration-resistant prostate cancer (mCRPC)." Journal of clinical oncology : official journal of the American Society of Clinical Oncology 29, no. 7_suppl (March 2011): 185-.
  - Sonpavde, G, Pond, GR, Berry, WR, De Wit, R, Eisenberger, MA, Tannock, I, and Armstrong, AJ. "Association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapy." Journal of Clinical Oncology 29, no. 7_suppl (March 2011): 118-118. Full Text
  - Sonpavde, G, Pond, GR, Berry, WR, De Wit, R, Eisenberger, MA, Tannock, I, and Armstrong, AJ. "Association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapy." Journal of clinical oncology : official journal of the American Society of Clinical Oncology 29, no. 7_suppl (March 2011): 118-.
  - Armstrong, AJ. "Clinical update: Epithelial-mesenchymal transition in cancer progression." Clinical Advances in Hematology and Oncology 9, no. 12 (2011): 941-943.
  - Armstrong, AJ. "Radiotherapy aids survival in clinically staged, node+ prostate Ca: Commentary." Oncology Report , no. JANUARY (2011): 25--.
  - Armstrong, AJ. "RT mode has an impact on pelvic fracture risk in older patients: Commentary." Oncology Report , no. JANUARY (2011): 25--.
  - Bitting, RL, Armstrong, AJ, and George, DJ. "Management Options in Advanced Prostate Cancer: What is the Role for Sipuleucel-T?." Clin Med Insights Oncol 5 (2011): 325-332. Full Text Link to Item
  - Chekeni, FB, Elliott, MR, Sandilos, JK, Walk, SF, Kinchen, JM, Lazarowski, ER, Armstrong, AJ, Penuela, S, Laird, DW, Salvesen, GS, Isakson, BE, Bayliss, DA, and Ravichandran, KS. "Pannexin 1 channels mediate 'find-me' signal release and membrane permeability during apoptosis." Nature 467, no. 7317 (October 14, 2010): 863-867. Full Text Link to Item
  - Armstrong, AJ, Netto, GJ, Rudek, MA, Halabi, S, Wood, DP, Creel, PA, Mundy, K, Davis, SL, Wang, T, Albadine, R, Schultz, L, Partin, AW, Jimeno, A, Fedor, H, Febbo, PG, George, DJ, Gurganus, R, De Marzo, AM, and Carducci, MA. "A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer." Clin Cancer Res 16, no. 11 (June 1, 2010): 3057-3066. Full Text Link to Item
  - Armstrong, AJ, and George, DJ. "Optimizing the use of docetaxel in men with castration-resistant metastatic prostate cancer." Prostate Cancer Prostatic Dis 13, no. 2 (June 2010): 108-116. (Review) Full Text Link to Item
  - Armstrong, AJ, George, DJ, and Halabi, S. "Serum lactate dehydrogenase (LDH) as a biomarker for survival with mTor inhibition in patients with metastatic renal cell carcinoma (RCC)." JOURNAL OF CLINICAL ONCOLOGY 28, no. 15 (May 20, 2010). Link to Item
  - Armstrong, AJ, Kemeny, G, Turnbull, JD, Chao, C, Winters, C, Fesko, YA, Bradley, DA, Halabi, S, George, DJ, and Garcia-Blanco, M. "Impact of temsirolimus and anti-androgen therapy on circulating tumor cell (CTC) biology in men with castration-resistant metastatic prostate cancer (CRPC): A phase II study." Journal of Clinical Oncology 28, no. 15_suppl (May 20, 2010): TPS249-TPS249. Full Text
  - Pili, R, Haggman, M, Stadler, WM, Gingrich, JR, Assikis, VJ, Bjork, A, Forsberg, G, Carducci, MA, and Armstrong, AJ. "A randomized, multicenter, international phase II study of tasquinimod in chemotherapy naive patients with metastatic castrate-resistant prostate cancer (CRPC)." JOURNAL OF CLINICAL ONCOLOGY 28, no. 15 (May 20, 2010). Link to Item
  - Pond, GR, Sonpavde, G, Berry, WR, De Wit, R, Armstrong, AJ, Eisenberger, MA, and Tannock, I. "Use of changes in serum alkaline phosphatase to predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy: A retrospective analysis of the TAX327 trial." Journal of Clinical Oncology 28, no. 15_suppl (May 20, 2010): 4637-4637. Full Text
  - Sankhala, KK, Chiorean, EG, Armstrong, AJ, Borad, MJ, Traynor, AM, Gadgeel, SM, Langmuir, VK, Eng, C, Kroll, S, and Burris, H. "Phase I/II study of TH-302 in combination with docetaxel in patients with solid tumors including NSCLC and castrate-resistant prostate cancer (CRPC)." Journal of Clinical Oncology 28, no. 15_suppl (May 20, 2010): e13527-e13527. Full Text
  - Turnbull, JD, Armstrong, AJ, Morris, K, Wood, SEY, Voyles, S, Fesko, YA, and George, DJ. "A single arm phase Ib study of RAD001 and sunitinib in patients with advanced renal cell carcinoma (RCC)." JOURNAL OF CLINICAL ONCOLOGY 28, no. 15 (May 20, 2010). Link to Item
  - Armstrong, AJ, Tannock, IF, de Wit, R, George, DJ, Eisenberger, M, and Halabi, S. "The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival." Eur J Cancer 46, no. 3 (February 2010): 517-525. Full Text Link to Item
  - Armstrong, AJ, Garrett-Mayer, E, de Wit, R, Tannock, I, and Eisenberger, M. "Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer." Clin Cancer Res 16, no. 1 (January 1, 2010): 203-211. Full Text Link to Item
  - Armstrong, AJ, Gebre, AK, Parks, JS, and Hedrick, CC. "ATP-binding cassette transporter G1 negatively regulates thymocyte and peripheral lymphocyte proliferation." J Immunol 184, no. 1 (January 1, 2010): 173-183. Full Text Link to Item
  - Armstrong, AJ. "Metastatic CRPC survival doesn't improve with added bevacizumab: Comment." Oncology Report , no. JULY-AUGUST (2010): 23--.
  - Armstrong, AJ. "Denosumab prevents or stalls skeletal events in prostate cancer: Comment." Oncology Report , no. JULY-AUGUST (2010): 23--.
  - Armstrong, AJ. "Cabazitaxel prolongs survival in late metastatic CRPC: Commentary." Oncology Report , no. MARCH-APRIL (2010): 22--.
  - Armstrong, AJ. "IMPACT update: Survival benefit of sipuleucel-T is durable: Commentary." Oncology Report , no. MARCH-APRIL (2010): 23--.
  - Armstrong, AJ, and Febbo, PG. "Using surrogate biomarkers to predict clinical benefit in men with castration-resistant prostate cancer: an update and review of the literature." Oncologist 14, no. 8 (August 2009): 816-827. (Review) Full Text Link to Item
  - Araujo, J, Armstrong, AJ, Braud, EL, Posadas, E, Lonberg, M, Gallick, GE, Trudel, GC, Paliwal, P, Agrawal, S, and Logothetis, CJ. "Dasatinib and docetaxel combination treatment for patients with castration-resistant progressive prostate cancer: A phase I/II study (CA180086)." Journal of clinical oncology : official journal of the American Society of Clinical Oncology 27, no. 15_suppl (May 2009): 5061-.
  - Armstrong, AJ, Halabi, S, Tannock, IF, George, DJ, DeWit, R, and Eisenberger, M. "Development of risk groups in metastatic castration-resistant prostate cancer (mCRPC) to facilitate the identification of active chemotherapy regimens." Journal of clinical oncology : official journal of the American Society of Clinical Oncology 27, no. 15_suppl (May 2009): 5137-.
  - Armstrong, AJ, Halabi, S, de Wit, R, Tannock, IF, and Eisenberger, M. "The relationship of body mass index and serum testosterone with disease outcomes in men with castration-resistant metastatic prostate cancer." Prostate Cancer Prostatic Dis 12, no. 1 (2009): 88-93. Full Text Link to Item
  - Armstrong, AJ. "Bevacizumab increases toxicity, VTE in bladder cancer: Commentary." Oncology Report , no. FALL (2009): 24--.
  - Armstrong, AJ. "TroVax vaccine delivers mixed results in renal cell carcinoma: Commentary." Oncology Report , no. WINT (2009): 26--.
  - Armstrong, AJ. "Second vaccine shows improved survival in prostate cancer: Commentary." Oncology Report , no. FALL (2009): 25--.
  - Armstrong, AJ, Creel, P, Turnbull, J, Moore, C, Jaffe, TA, Haley, S, Petros, W, Yenser, S, Gockerman, JP, Sleep, D, Hurwitz, H, and George, DJ. "A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer." Clin Cancer Res 14, no. 19 (October 1, 2008): 6270-6276. Full Text Link to Item
  - Figlin, RA, Brown, E, Armstrong, AJ, Akerley, W, Benson, AB, Burstein, HJ, Ettinger, DS, Febbo, PG, Fury, MG, Hudes, GR, Kies, MS, Kwak, EL, Morgan, RJ, Mortimer, J, Reckamp, K, Venook, AP, Worden, F, and Yen, Y. "NCCN Task Force Report: mTOR inhibition in solid tumors." J Natl Compr Canc Netw 6 Suppl 5 (September 2008): S1-20. (Review) Link to Item
  - Armstrong, AJ, and George, DJ. "New drug development in metastatic prostate cancer." Urol Oncol 26, no. 4 (July 2008): 430-437. (Review) Full Text Link to Item
  - Armstrong, AJ, Halabi, S, Tannock, IF, Ronald, D, and Eisenberger, MA. "The relationship of body mass index and serum testosterone with disease outcomes in men with castration-resistant metastatic prostate cancer." JOURNAL OF CLINICAL ONCOLOGY 26, no. 15 (May 20, 2008). Full Text Link to Item
  - Whang, YE, Moore, CN, Armstrong, AJ, Rathmell, WK, Godley, PA, Crane, JM, Grigson, GI, Morris, K, Watkins, CP, and George, DJ. "A phase II trial of lapatinib in hormone refractory prostate cancer." JOURNAL OF CLINICAL ONCOLOGY 26, no. 15 (May 20, 2008). Link to Item
  - Armstrong, AJ, Garrett-Mayer, EL, and Eisenberger, M. "Re: Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens." J Natl Cancer Inst 100, no. 9 (May 7, 2008): 681-682. (Letter) Full Text Link to Item
  - Ramiah, V, George, DJ, and Armstrong, AJ. "Clinical endpoints for drug development in prostate cancer." Curr Opin Urol 18, no. 3 (May 2008): 303-308. (Review) Full Text Link to Item
  - Armstrong, AJ. "Commentary." Oncology Report , no. FALL (2008): 38--.
  - Armstrong, AJ. "Abiraterone acetate active in castration-resistant trials: Commentary." Oncology Report , no. FALL (2008): 39--.
  - Armstrong, AJ. "Thalidomide prolongs PFS following androgen failure: Commentary." Oncology Report , no. FALL (2008): 40--.
  - Chen, FL, Armstrong, AJ, and George, DJ. "Cell signaling modifiers in prostate cancer." Cancer J 14, no. 1 (January 2008): 40-45. (Review) Full Text Link to Item
  - Armstrong, AJ, Garrett-Mayer, ES, Yang, Y-CO, de Wit, R, Tannock, IF, and Eisenberger, M. "A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis." Clin Cancer Res 13, no. 21 (November 1, 2007): 6396-6403. Full Text Link to Item
  - Armstrong, AJ, and George, DJ. "Satraplatin in the treatment of hormone-refractory metastatic prostate cancer." Ther Clin Risk Manag 3, no. 5 (October 2007): 877-883. Link to Item
  - Armstrong, AJ, Garrett-Mayer, E, Ou Yang, Y-C, Carducci, MA, Tannock, I, de Wit, R, and Eisenberger, M. "Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer." J Clin Oncol 25, no. 25 (September 1, 2007): 3965-3970. Full Text Link to Item
  - Srinivasan, R, Armstrong, AJ, Dahut, W, and George, DJ. "Anti-angiogenic therapy in renal cell cancer." BJU Int 99, no. 5 Pt B (May 2007): 1296-1300. (Review) Full Text Link to Item
  - Armstrong, AJ, Febbo, PG, George, DJ, and Moul, J. "Systemic strategies for prostate cancer." Minerva Urol Nefrol 59, no. 1 (March 2007): 11-25. (Review) Link to Item
  - Armstrong, AJ, Garrett-Mayer, E, Eisenberger, M, Tannock, I, and Wit, RD. "In reply [12]." Journal of Clinical Oncology 25, no. 35 (2007): 5674--. Full Text
  - Mendiratta, P, Armstrong, AJ, and George, DJ. "Current standard and investigational approaches to the management of hormone-refractory prostate cancer." Rev Urol 9 Suppl 1 (2007): S9-S19. Link to Item
  - Armstrong, AJ, and Carducci, MA. "New drugs in prostate cancer." Curr Opin Urol 16, no. 3 (May 2006): 138-145. (Review) Full Text Link to Item
  - Armstrong, AJ, and Eisenberger, M. "Does gonadotropin-releasing-hormone agonist therapy for prostate cancer increase the risk of fracture?." Nat Clin Pract Urol 3, no. 5 (May 2006): 246-247. Full Text Link to Item
  - Armstrong, AJ, and Carducci, MA. "Advanced prostate cancer: the future." Can J Urol 12 Suppl 2 (June 2005): 42-47. (Review) Link to Item
  - Armstrong, AJ, and Carducci, MA. "Chemotherapy for advanced prostate cancer: results of new clinical trials and future studies." Curr Oncol Rep 7, no. 3 (May 2005): 220-227. (Review) Link to Item
  - Armstrong, AJ, and Carducci, MA. "Novel therapeutic approaches to advanced prostate cancer." Clin Adv Hematol Oncol 3, no. 4 (April 2005): 271-282. (Review) Link to Item
  - Armstrong, AJ, McMahon, BT, West, SL, and Lewis, A. "Workplace discrimination and cumulative trauma disorders: the national EEOC ADA research project." Work 25, no. 1 (2005): 49-56. Link to Item
  - Eck, SL, and Armstrong, A. "EpCAM is an important suppressor of anti-tumor immunity [2]." Cancer Biology and Therapy 4, no. 4 (2005): e129-.
  - Armstrong, A, and Eck, SL. "EpCAM: A new therapeutic target for an old cancer antigen." Cancer Biology and Therapy 2, no. 4 (2003): 320-325. Full Text
  - Nightingale, RW, Camacho, DL, Armstrong, AJ, Robinette, JJ, and Myers, BS. "Inertial properties and loading rates affect buckling modes and injury mechanisms in the cervical spine." J Biomech 33, no. 2 (February 2000): 191-197. Link to Item
  - Nightingale, RW, Armstrong, AJ, Camacho, DL, and Myers, BS. "Cervical spine buckling: The effects of vertebral mass and loading rate." American Society of Mechanical Engineers, Bioengineering Division (Publication) BED 36 (1997): 231-232.
  - Fukasawa, K, Zhou, R, Matten, WT, Armstrong, AJ, Daar, I, Oskarsson, M, Sathyanarayana, BK, Maclvor, L, Wood, TG, and Vande Woude, GF. "Mutagenic analysis of functional domains of the mos proto-oncogene and identification of the sites important for MAPK activation and DNA binding." Oncogene 11, no. 8 (October 19, 1995): 1447-1457. Link to Item
  - Bevan, TD, Manninen, AJ, Cook, JB, Armstrong, AJ, Hook, JR, and Hall, HE. "Vortex Mutual Friction in Rotating Superfluid 3He-B." Phys Rev Lett 74, no. 5 (January 30, 1995): 750-753. Full Text Link to Item
  - Mullins, TR, Dmitriev, VV, Armstrong, AJ, Manninen, AJ, Hook, JR, and Hall, HE. "Identification of the order parameter of 3He-A using low-field NMR measurements." Phys Rev Lett 72, no. 26 (June 27, 1994): 4117-4120. Full Text Link to Item
  - Tang, Y, Armstrong, AJ, Mockler, RC, and O'Sullivan, WJ. "Free-expansion melting of a colloidal monolayer." Phys Rev Lett 62, no. 20 (May 15, 1989): 2401-2404. Full Text Link to Item
  - Bender, DA, Armstrong, AJ, Monkhouse, CR, and Richardson, JP. "Changes in pancreatic tryptophan in the rat in response to fasting. The effect of B-cytotoxic agents and variation through the oestrous cycle." Pflugers Arch 356, no. 3 (1975): 245-251. Link to Item
- Other Articles
  - Somarelli, JA, Somarelli, JA, Schaeffer, D, Schaeffer, D, Marengo, MS, Marengo, MS, Bepler, T, Bepler, T, Rouse, D, Buckley, AF, Epstein, JI, Armstrong, AJ, Garcia-Blanco, MA, and Garcia-Blanco, MA. "Abstract SS02-02: A long walk from FGFR2 alternative splicing to cancer progression." Cancer Epidemiology Biomarkers & Prevention 23, no. 11 Supplement (November 2014): SS02-02-SS02-02. Full Text
  - Armstrong, AJ, Moul, JW, and George, DJ. "What to order from the prostate cancer treatment menu?." Oncology (Williston Park) 26, no. 1 (January 2012): 84-88. Link to Item
  - Armstrong, AJ, Moul, JW, and George, DJ. "What to Order From the Prostate Cancer Treatment Menu? THE CRAWFORD/FLAIG ARTICLE REVIEWED." ONCOLOGY-NEW YORK 26, no. 1 (January 2012): 84-+. Link to Item
Teaching & Mentoring
Recent Courses
- PHARM 493: Research Independent Study 2018
- PHARM 494: Research Independent Study 2018

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.

Education, Training, & Certifications

Duke Appointment History

In the News

Global Scholarship

Research

Teaching

Selected Grants

Selected Publications

Book Sections

Conference Papers

Journal Articles

Other Articles

Recent Courses